sulfamethoxazole profile

Sulfamethoxazole is a synthetic antibacterial drug in the sulfonamide class. It inhibits the synthesis of dihydrofolic acid, which is a crucial precursor for bacterial growth. It is typically used in combination with trimethoprim, forming the cotrimoxazole formulation, which has a broad spectrum of activity against various bacterial infections. It is particularly effective against gram-positive and gram-negative bacteria, including those causing urinary tract infections, pneumonia, and traveler's diarrhea. Sulfamethoxazole's mechanism of action involves competitively inhibiting the enzyme dihydropteroate synthase, which is responsible for the synthesis of dihydrofolic acid in bacteria. This leads to the inhibition of bacterial DNA synthesis and ultimately bacterial growth. The combination of sulfamethoxazole with trimethoprim enhances its effectiveness by inhibiting different steps in the folate biosynthesis pathway, resulting in a synergistic effect. Research on sulfamethoxazole focuses on optimizing its efficacy, understanding its pharmacokinetics and pharmacodynamics, exploring potential drug resistance mechanisms, and investigating its potential applications in various medical settings.'

Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5329
CHEMBL ID	443
CHEBI ID	9332
SCHEMBL ID	3656
MeSH ID	M0020750

Synonym
BIDD:GT0731
CHEBI:9332 ,
4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
3-(p-aminophenylsulfonamido)-5-methylisoxazole
unii-je42381tnv
je42381tnv ,
sulfamethoxazole [usan:usp:inn:ban:jan]
MLS001074165
bdbm50029770
NCGC00016533-12
NCGC00016533-11
4-amino-n-(5-methyl-isoxazol-3-yl)-benzene sulfonamide
BB 0242379
AB00052099-16
BRD-K28494619-001-05-0
4-amino-n-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
smr000058223
DIVK1C_000649
KBIO1_000649
SPECTRUM_000994
PRESTWICK2_000177
PRESTWICK_453
NCGC00016533-01
cas-723-46-6
IDI1_000649
SPECTRUM5_000982
smx ,
4-amino-n-(5-methylisoxazol-3-yl)benzenesulfonamide
BPBIO1_000081
BSPBIO_002028
BSPBIO_000073
OPREA1_285680
OPREA1_114486
NCGC00021995-03
AB00052099
A047 ,
sulfamethoxazolum [inn-latin]
5-methyl-3-sulphanil-amidoisoxazole
sulphamethoxazol
ccris 567
sulphamethylisoxazole
n1-(5-methyl-3-isoxazolyl)sulfanilamide
sulfamethoxizole
azo-gantanol
solfametossazolo [dcit]
urobak
brn 0226453
n(sup 1)-(5-methyl-3-isoxazolyl)sulphanilamide
gantanol-ds
sulfanilamide, n(1)-(5-methyl-3-isoxazolyl)-
einecs 211-963-3
5-methyl-3-sulfanilamidoisoxazole
n(sup 1)-(5-methyl-3-isoxazolyl)sulfanilamide
3-sulphanilamido-5-methylisoxazole
hsdb 3186
sulpha-methoxizole
nsc 147832
n'-(5-methylisoxazol-3-yl)sulphanilamide
sulfametoxazol [inn-spanish]
gamazole
3-(para-aminophenylsulphonamido)-5-methylisoxazole
C07315
723-46-6
sulfamethoxazole
n'-(5-methyl-3-isoxazole)sulfanilamide
4-amino-n-(5-methyl-3-isoxazolyl)benzenesulfonamide
nsc-147832
sulfamethoxazol
sulfanilamide, n'-(5-methyl-3-isoxazolyl)-
gantanol
benzenesulfonamide, 4-amino-n-(5-methyl-3-isoxazolyl)-
sulfanilamide, n1-(5-methyl-3-isoxazolyl)-
metoxal
sulfisomezole
bactrim
ro 4-2130
radonil
n'-(5-methyl-3-isoxazolyl)sulfanilamide
ro 6-2580/11
wln: t5noj c1 emswr dz
sinomin
simsinomin
sulphamethoxazole
ms 53
n(sup1)-(5-methyl-3-isoxazolyl)sulfanilamide
3-sulfanilamido-5-methylisoxazole
nsc147832
sulfamethylisoxazole
sulfamethalazole
5-methyl-3-sulfanylamidoisoxazole
DB01015
D00447
sulfamethoxazole (jp17/usp/inn)
PRESTWICK3_000177
NCGC00021995-04
NCGC00021995-05
MLS000069732 ,
MAYBRIDGE1_007190
KBIO2_006610
KBIOSS_001474
KBIO2_001474
KBIOGR_000749
KBIO2_004042
KBIO3_001528
SPECTRUM3_000584
NINDS_000649
SPECTRUM2_000788
SPBIO_000896
SPECTRUM4_000345
PRESTWICK1_000177
PRESTWICK0_000177
SPBIO_001994
SPECTRUM1500550
NCGC00016533-02
MLS001055354
STK007988
HMS2092K03
AC-11118
AKOS000200952
HMS561O18
CHEMBL443 ,
sulfamethoxazolum
stx-608
ro-4-2130
HMS502A11
inchi=1/c10h11n3o3s/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6h,11h2,1h3,(h,12,13)
jlkigftwxxrpmt-uhfffaoysa-
HMS1568D15
HMS1921A21
NCGC00016533-05
NCGC00186654-01
HMS2095D15
HMS3259E06
BBL004554
08d ,
tox21_200353
NCGC00257907-01
4-amino-n-(5-methyl-3-isoxazoyl)benzenesulfonamide
nsc-757328
nsc757328
pharmakon1600-01500550
tox21_110480
dtxcid006064
dtxsid8026064 ,
solfametossazolo
sulfametoxazol
HMS2233L13
CCG-40166
NCGC00016533-03
NCGC00016533-04
NCGC00016533-10
NCGC00016533-06
NCGC00016533-07
NCGC00016533-08
NCGC00016533-09
[(4-aminophenyl)sulfonyl](5-methylisoxazol-3-yl)amine
sulphisomezole
BCP0726000283
FT-0602616
NCGC00016533-14
azo gantanol component sulfamethoxazole
sulfamethoxazole component of sulmeprim
sulfamethoxazole [who-dd]
sulfamethoxazole [mart.]
sulfamethoxazolum [who-ip latin]
sulfamethoxazole component of septra
sulfamethoxazole [orange book]
sulfamethoxazole component of uroplus
sulfamethoxazole component of cotrim d.s.
sulfamethoxazole [hsdb]
septra component sulfamethoxazole
sulfamethoxazole component of sulfamethoprim
sulfamethoxazole component of azo gantanol
sulfamethoprim component sulfamethoxazole
sulfamethoxazole [usan]
sulfamethoxazole [mi]
sulfamethoxazole [iarc]
cotrim d.s. component sulfamethoxazole
cotrim component sulfamethoxazole
bactrim component sulfamethoxazole
sulfamethoxazole component of bactrim
sulfamethoxazole [who-ip]
sulfamethoxazole component of sulfatrim
sulmeprim component sulfamethoxazole
sulfamethoxazole component of bactrim pediatric
sulfatrim component sulfamethoxazole
sulfamethoxazole component of bactrim ds
sulfamethoxazole [vandf]
bactrim ds component sulfamethoxazole
sulfamethoxazole [usp-rs]
sulfamethoxazole component of cotrim
uroplus component sulfamethoxazole
bactrim pediatric component sulfamethoxazole
sulfamethoxazole [jan]
sulfamethoxazole [usp monograph]
co-trimethoxazole component sulfamethoxazole
sulfamethoxazole [ep monograph]
sulfamethoxazole [inn]
EPITOPE ID:114999
AB00052099-14
S1915
HMS3372M22
HY-B0322
NC00537
SCHEMBL3656
tox21_110480_1
MLS006011871
Q-201762
septran (salt/mix)
3-(p-aminobenzenesulfonamido)-5-methylisoxazole
eusaprim (salt/mix)
co-trimoxazole (salt/mix)
component of bactrim (salt/mix)
component of azo gantanol (salt/mix)
5-methyl-3-sulfonylamidoisoxazole
septrin (salt/mix)
OPERA_ID_882
AB00052099_18
AB00052099_17
mfcd00010546
sulfamethoxazole, certified reference material, tracecert(r)
4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide
BS-3542
stx 608
4-amino-n-(5-methyl-3-isoxazolyl)-benzenesulfonamide
sr-01000000217
SR-01000000217-2
sulfamethoxazole, vetranal(tm), analytical standard
sulfamethoxazole, united states pharmacopeia (usp) reference standard
Z57198677
HMS3655O22
sulfamethoxazole, european pharmacopoeia (ep) reference standard
sulfamethoxazole, analytical standard
sulfamethoxazole, pharmaceutical secondary standard; certified reference material
sulfamethoxazole; 4-amino-n-(5-methylisoxazol-3-yl)benzenesulfonamide
SR-01000000217-3
SBI-0051524.P003
129378-89-8
HMS3712D15
n1-(5-methyl-3-isoxazolyl)sulphanilamide
ndimethyl1-(5-methyl-3-isoxazolyl)-sulfanilamide
n^1-(5-methyl-3-isoxazolyl)-sulfanilamide
n1-(5-methyl-3-isoxazolyl)-sulfanilamide
n'-(5-methyl-3-isoxazolyl)-sulfanilamide
sulfamethoxazole(usan)
sulfamethoxazole, british pharmacopoeia (bp) reference standard
SW196670-3
4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; smx; smz
Q415843
SY018888
3-methyl-1-(4-sulfoamidophenyl)-5-pyra&
F12027
sulfamethoxazole,(s)
sulfamethoxazole 100 microg/ml in acetonitrile
BCP02881
BRD-K28494619-001-15-9
BRD-K28494619-001-26-6
EN300-18400
gtpl10933
ro-42130
4-amino-n-(5-methylisoxazol-3-yl)benzenesulphonamide
144930-01-8
STARBLD0000281
rp-2145
sulfamethoxazole 1000 microg/ml in acetonitrile
sulfamethoxazole (ep monograph)
n(1)-(5-methyl-3-isoxazolyl)sulfanilamide
4-amino-n-(5-methyl-3-isoazolyl)benzenesulfonamide
j01ec01
sulfamethoxazole (mart.)
sulfamethoxazolum (inn-latin)
sulfamethoxazole (iarc)
sulfametoxazolo
n'-(5-methyl-3-isoxazoylyl)sulfanilamide
sulfametoxazol (inn-spanish)
sulfamethoxazole (usan:usp:inn:ban:jan)
sulfamethoxazole (usp monograph)
sulfamethoxazole (usp-rs)

Excerpt	Reference	Relevance
"Sulfamethoxazole (SMX) is a widespread broad-spectrum bacteriostatic antibiotic. "	( Sulfamethoxazole induces brain capillaries toxicity in zebrafish by up-regulation of VEGF and chemokine signalling. Chen, J; Luo, L; Xu, Y, 2022)	3.61
"Sulfamethoxazole (SMZ) is an important antibiotic used to prevent and treat infections in both clinical settings and animal husbandry. "	( Association of long-term effects of low-level sulfamethoxazole with ovarian lipid and amino acid metabolism, sex hormone levels, and oocyte maturity in zebrafish. Dong, T; Huang, L; Li, H; Qiu, Y; Shi, Y; Wu, Y; Yu, K; Yu, X, 2022)	2.42
"Sulfamethoxazole (SMX), is a ubiquitous antibiotic in the aquatic environment and received concerns on its health hazards, especially its sub-lethal effects on non-target organisms which were remained largely unknown. "	( Assessment of sulfamethoxazole toxicity to marine mussels (Mytilus galloprovincialis): Combine p38-MAPK signaling pathway modulation with histopathological alterations. Chen, S; Di, Y; Li, R; Li, T; Qu, M; Xu, J; Yang, Y, 2023)	2.71
"Sulfamethoxazole (SFM) is a commonly used antibiotic that is released into the environment through human and animal wastes."	( A hybrid technique for sulfamethoxazole (SFM) removal using Enterobacter hormaechei HaG-7: Bio-electrokinetic degradation, pathway and toxicity. Mohan, H; Muthukumar Sathya, P; Seralathan, KK; Venkatachalam, J, 2023)	1.94
"Sulfamethoxazole (SMX) is a frequently detected antibiotic in the environment and has attracted much attention. "	( Sulfamethoxazole degradation by Aeromonas caviae and co-metabolism by the mixed bacteria. Chen, L; Lv, M; Wang, H; Wang, Q; Wang, X, 2023)	3.8
"Sulfamethoxazole (SMX) is an extensively applied antibiotic frequently detected in municipal wastewater, which cannot be efficiently removed by conventional biological wastewater processes. "	( Fabrication of an intimately coupled photocatalysis and biofilm system for removing sulfamethoxazole from wastewater: Effectiveness, degradation pathway and microbial community analysis. Hou, J; Liu, Q; Miao, L; Wu, J; Yang, Z; Zeng, Y, 2023)	2.58
"Sulfamethoxazole (SMX) is a general antibiotic that is frequently identified in wastewater and surface water. "	( Degradation pathways, microbial community and electricity properties analysis of antibiotic sulfamethoxazole by bio-electro-Fenton system. Hua, T; Li, B; Li, F; Li, S; Yuan, CS; Zhu, X, 2020)	2.22
"Sulfamethoxazole (SMZ) is a kind of sulfonamides antibiotic, which is widely used in human life. "	( Effects of Sulfamethoxazole Exposure on the Growth, Antioxidant System of Chlorella vulgaris and Microcystis aeruginosa. Dong, X; Hou, L; Hou, W; Jia, R; Lu, N; Sun, S; Wang, M; Xu, L; Zhao, Q, 2020)	2.39
"Sulfamethoxazole (SMX) is a common antibiotic prescribed for treating infections, which is frequently detected in the effluent of conventional wastewater treatment plants (WWTPs). "	( Biological conversion of sulfamethoxazole in an autotrophic denitrification system. Sun, F; Wu, D; Yan, W; Zhang, L; Zhou, Y, 2020)	2.3
"Sulfamethoxazole (SMX) is a fat-soluble antibiotic, an eight weeks feeding trial was conducted to investigate the interactions between dietary lipid levels and chronic exposure of legal aquaculture dose of sulfamethoxazole in juvenile largemouth bass Micropterus salmoides, and evaluated the possible human health risk."	( Interactions between dietary lipid levels and chronic exposure of legal aquaculture dose of sulfamethoxazole in juvenile largemouth bass Micropterus salmoides. Liu, Y; Niu, J; Tan, B; Tian, L; Xie, S; Yin, P, 2020)	1.5
"Sulfamethoxazole (SMX) is a veterinary antibiotic that is not efficiently removed from wastewater by routine treatment and therefore can be detected widely in the environment. "	( Anaerobic Transformation and Detoxification of Sulfamethoxazole by Sulfate-Reducing Enrichments and Adrian, L; Birkigt, J; Ouyang, WY; Richnow, HH, 2021)	2.32
"Sulfamethoxazole (SMX) is a commonly used antibiotic which accumulation can favor the development of antimicrobial resistance. "	( An innovative and simple all electrochemical approach to functionalize electrodes with a carbon nanotubes/polypyrrole molecularly imprinted nanocomposite and its application for sulfamethoxazole analysis. Corvaglia, S; Malitesta, C; Pompa, PP; Turco, A, 2021)	2.26
"Sulfamethoxazole (SMX) is a widely used antibiotic that is incompletely metabolized in the body."	( Bioremoval and tolerance study of sulfamethoxazole using whole cell Boontanon, N; Boontanon, SK; Piyaviriyakul, P, 2021)	1.62
"Sulfamethoxazole (SMX) is a common medicine prescribed to treat infections. "	( Biodegradation of sulfamethoxazole in bacteria from three different origins. Ashfaq, M; Hu, A; Li, J; Mulla, SI; Suanon, F; Sun, Q; Yu, CP, 2018)	2.26
"Sulfamethoxazole (SMX) is a sulfonamide antibiotic, widely used as curative and preventive drug for human, animal, and aquaculture bacterial infections. "	( Contribution of biotic and abiotic factors in the natural attenuation of sulfamethoxazole: A path analysis approach. Chen, M; Hu, A; Li, Y; Lin, L; Rashid, A; Sun, Q; Wang, H; Yu, CP, 2018)	2.16
"Sulfamethoxazole (SMX) is a widespread and persistent antibiotic pollutant in the aquatic environment. "	( Degradation of sulfamethoxazole by ionizing radiation: Kinetics and implications of additives. Wang, J; Zhuan, R, 2019)	2.31
"Sulfamethoxazole (SMZ) which is an antibiotic, caused significant inhibition of aggregation which was evident by number of biophysical techniques."	( An antibiotic (sulfamethoxazole) stabilizes polypeptide (human serum albumin) even under extreme condition (elevated temperature). Furkan, M; Khan, AN; Khan, RH; Sidddiqi, MK, 2019)	1.59
"Sulfamethoxazole is a common antibiotic that is frequently detected in wastewater and surface water. "	( Biodegradation and metabolic pathway of sulfamethoxazole by Pseudomonas psychrophila HA-4, a newly isolated cold-adapted sulfamethoxazole-degrading bacterium. Cai, R; Cui, D; Jiang, B; Li, A; Ma, F; Wang, Y, 2014)	2.11
"Sulfamethoxazole (SMX) is a persistent sulfonamide antibiotic drug used in the veterinary and human medical sectors and is widely detected in natural waters. "	( Speciation study in the sulfamethoxazole-copper-pH-soil system: implications for retention prediction. Brimo, K; Martins, JM; Morel, MC; Spadini, L, 2014)	2.15
"Sulfamethoxazole (SMX) is an old sulfonamide antibiotic that was launched first in combination with trimethoprim in 1969 by F.Hoffmann-La Roche. "	( Aquatic environmental risk assessment for human use of the old antibiotic sulfamethoxazole in Europe. Straub, JO, 2016)	2.11
"Sulfamethoxazole (SMX) is a bacteriostatic antibiotic ubiquitously found in the aquatic environment. "	( Phototransformation of sulfamethoxazole under simulated sunlight: Transformation products and their antibacterial activity toward Vibrio fischeri. Gmurek, M; Horn, H; Majewsky, M, 2015)	2.17
"Sulfamethoxazole (SMX) is a commonly applied antibiotic for treating urinary tract infections; however, allergic reactions and skin eczema are known side effects that are observed for all sulfonamides. "	( SERS as an analytical tool in environmental science: The detection of sulfamethoxazole in the nanomolar range by applying a microfluidic cartridge setup. Cialla-May, D; Huebner, U; Liebold, F; Patze, S; Popp, J; Weber, K, 2017)	2.13
"Sulfamethoxazole (SMX) is an antibiotic of growing environmental concern. "	( Development of sulfamethoxazole-imprinted polymers for the selective extraction from waters. Palm, BS; Schiller, M; Steinfeld, U; Valtchev, M, 2009)	2.15
"Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. "	( Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. Feng, WL; Gao, F; Ge, RL; Guan, W; Li, XY; Li, ZQ, 2009)	2.07
"Sulfamethoxazole (SMX) is an anti-bacterial sulfonamide. "	( Voltammetric determination of sulfamethoxazole at a multiwalled carbon nanotube modified glassy carbon sensor and its application studies. Girish Kumar, K; Issac, S, 2009)	2.08
"Sulfamethoxazole (SMX) is an important antibiotic in the management of patients with cystic fibrosis, but allergic reactions may develop thus restricting therapy. "	( Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis. Conway, S; Lavergne, SN; Naisbitt, DJ; Park, BK; Peckham, D; Whitaker, P, 2010)	2.06
"Sulfamethoxazole (SM) is a sulfonamide bacteriostatic antibiotic. "	( Differential pulse voltammetric determination and catalytic oxidation of sulfamethoxazole using [5,10,15,20- tetrakis (3-methoxy-4-hydroxy phenyl) porphyrinato] Cu (II) modified carbon paste sensor. Girish Kumar, K; Joseph, R, 2010)	2.03
"Sulfamethoxazole (SMX) is a synthetic antibiotic widely applied as a bacteriostatic drug to treat a number of diseases. "	( Study of the toxicity of sulfamethoxazole and its degradation products in water by a bioluminescence method during application of the electro-Fenton treatment. Aaron, JJ; Dirany, A; Efremova Aaron, S; Oturan, MA; Oturan, N; Sirés, I, 2011)	2.12
"Sulfamethoxazole (SMX) is a commonly used antibiotic for prevention of infectious diseases associated with HIV/AIDS and immune-compromised states. "	( Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. Curtis, A; Koletar, SL; Papp, AC; Para, MF; Wang, D, 2012)	2.04
"Sulfamethoxazole (SMX) is an effective drug for the management of opportunistic infections, but its use is limited by hypersensitivity reactions, particularly in HIV-infected patients. "	( Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Bajad, SU; Graziano, FM; Guzinski, MV; Kurian, JR; Lavergne, SN; Maki, JE; Trepanier, LA; Yoder, AR, 2006)	2
"Sulfamethoxazole (SMX) is a bacteriostatic antibiotic largely used for diverse types of illness. "	( Sulfamethoxazole abatement by means of ozonation. Contreras, S; Dantas, RF; Esplugas, S; Sans, C, 2008)	3.23
"Sulfamethoxazole (SMX) is a widely used antibiotic which has been detected in surface water samples in the ng/L range and also detected in drinking water samples. "	( Impact of degradation products of sulfamethoxazole on mammalian cultured cells. Huot, JC; Leask, RL; Rodayan, A; Rouleau, L; Roy, R; Yargeau, V, 2008)	2.07

Excerpt	Reference	Relevance
"Sulfamethoxazole (SMX) has a high concentration and detection frequency in aquatic environments due to the poor removal efficiency of traditional biological treatment processes. "	( Performance and mechanism of sulfamethoxazole removal in different bioelectrochemical technology-integrated constructed wetlands. Chen, Y; Guo, X; Liu, X; Liu, Y; Lu, S; Wang, Y; Wu, F; Zhang, J, 2021)	2.36
"Sulfamethoxazole (SMX) has a high concentration and detection frequency in aquatic environments due to the poor removal efficiency of traditional biological treatment processes. "	( Performance and mechanism of sulfamethoxazole removal in different bioelectrochemical technology-integrated constructed wetlands. Chen, Y; Guo, X; Liu, X; Liu, Y; Lu, S; Wang, Y; Wu, F; Zhang, J, 2021)	2.36
"Sulfamethoxazole (SMX) has been widely detected in various environments and its potential environmental risks have caused great concerns. "	( Responses of microbial interactions and functional genes to sulfamethoxazole in anammox consortia. Gao, X; Hu, M; Liu, S; Liu, X; Wang, X; Ya, T; Zhang, M; Zhang, T, 2023)	2.6
"Sulfamethoxazole (SMX) has been commonly detected in wastewater treatment plant (WWTP) effluents. "	( Biodegradation of sulfamethoxazole by microalgae-bacteria consortium in wastewater treatment plant effluents. da Cunha, CCRF; da Fonseca Santiago, A; da Silva Rodrigues, DA; de Barros, ALC; de Cássia Franco Afonso, RJ; de Queiroz Silva, S; E Castro, PBN; Freitas, MG; Pereira, AR, 2020)	2.33
"Sulfamethoxazole (SMX) has attracted much attention due to its high probability of detection in the environment. "	( Biotransformation mechanism of Vibrio diabolicus to sulfamethoxazole at transcriptional level. Chen, L; Jiang, Y; Lv, M; Wang, H; Wang, Q; Wang, X, 2021)	2.31

Excerpt	Reference	Relevance
"Treatment with sulfamethoxazole (SMX) can lead to hypersensitivity reactions. "	( Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Burkhart, C; Farrell, J; Gordon, SF; Maggs, JL; Naisbitt, DJ; Park, BK; Pichler, WJ; Pirmohamed, M, 2002)	0.93
"Treatment with sulfamethoxazole trimethopin or streptomycin prevents complications and cures the affection in one or two weeks."	( [Reappearance of soft chancre: comments on the current epidemic in Paris (author's transl)]. Belaich, S; Bonvalet, D; Broissin, M; Civatte, J; Vallet, C, 1980)	0.6
"Treatment with sulfamethoxazole-trimethoprim for three days was compared with daily prophylaxis with sulfamethoxazole-trimethoprim or doxycycline."	( A cost-effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers' diarrhea. DuPont, HL; Ericsson, CD; Johnson, PC; Reves, RR, 1988)	0.61

Excerpt	Reference	Relevance
"Human diploid fibroblasts cultured in Dulbecco's Modified Eagle's medium (DME) were exposed to different concentrations of 15 antibiotics to determine the limiting toxic concentration."	( Toxicity of antibiotics on cultured human skin fibroblasts. Byarugaba, W; Koske-Westphal, T; Passarge, E; Rüdiger, HW; Wöhler, W, 1975)	0.25
" In addition, heterogeneity in cellular repair mechanisms and the diversity of the human immune response [22] may also contribute to the manifestation of the toxic effects of sulphonamides."	( Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity. Cribb, AE; Riley, RJ; Spielberg, SP, 1991)	0.28
" Using sulfamethoxazole hydroxylamine (SMX-HA) as a model compound, we report the use of a pH-sensitive fluorescent probe, 2',7'-biscarboxyethyl-5(6)-carboxyfluorescein (BCECF), to identify early subcellular targets of chemically synthesized, toxic drug metabolites in peripheral blood mononuclear cells."	( Cellular toxicity of sulfamethoxazole reactive metabolites--I. Inhibition of intracellular esterase activity prior to cell death. Dosch, HM; Leeder, JS; Spielberg, SP, 1991)	1.06
" SMX-HA was toxic to isolated MNL from mixed breed dogs (MBD) and Doberman Pinschers."	( An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs. Cribb, AE; Spielberg, SP, 1990)	0.28
" Adverse reactions occurred in 15 patients (50%)."	( Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. Dickinson, GM; Fischl, MA; La Voie, L, 1988)	0.59
" There were 39 toxic reactions, 15 of them serious: leukopenia (n = 23), abnormal liver functions (n = 14), skin changes (n = 12), gastrointestinal complaints (n = 10) and thrombocytopenia (n = 9)."	( [Side effects of trimethoprim-sulfamethoxazole in patients with AIDS]. de Matos-Marques, B; Pohle, HD; Ruf, B; Sixt, C; Weinke, T, 1988)	0.56
"Trimethoprim seems not to be a safe form of therapy in patients with a megaloblastic process; many of the toxic reactions reported with this drug may be on the basis of an unrecognized megaloblastic form of haemopoiesis."	( Toxicity of trimethoprim-sulphamethoxazole in patients with megaloblastic haemopoiesis. Chanarin, I; England, JM, 1972)	0.25
"During the decade 1968-1978 the Danish Board of Adverse Reactions to Drugs received 572 (6% of the total number) reports on hepatotoxicity."	( Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Andreasen, PB; Døssing, M, 1982)	0.26
"Variation in the formation and disposition of the hydroxylamine of (SMX-HA) is thought to play an important role in the pathogenesis of sulfamethoxazole (SMX)-induced idiosyncratic adverse drug reactions."	( In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity. Cribb, AE; Grant, DM; Hill, J; Josephy, PD; Miller, MA; Nakamura, H; Spielberg, SP; Uetrecht, J; Zahid, N, 1995)	0.74
"It has been suggested that the high rates of adverse reactions to sulfonamides among patients with AIDS may be related to an increased sensitivity to reactive drug metabolites among HIV-infected cells."	( Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells. Bird, IA; Dekaban, GA; Krause, R; Rieder, MJ, 1995)	0.29
" The mean time to first side effect was 12."	( Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count. Anderson, MD; Kennedy, CA; Lewis, DE; Oldfield, EC; Pimentel, JA; Weiss, PJ, 1993)	0.5
"The onset of cutaneous adverse effects attributable to sulfamethoxazole-trimethoprim therapy within 3 months after desensitization."	( Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Bricaire, F; Caumes, E; Guermonprez, G; Katlama, C; Lecomte, C, 1997)	0.81
"Of the 48 evaluable patients, 37 (77%) tolerated sulfamethoxazole-trimethoprim desensitization without toxic effects and continued to take sulfamethoxazole-trimethoprim daily."	( Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Bricaire, F; Caumes, E; Guermonprez, G; Katlama, C; Lecomte, C, 1997)	0.81
"The differential incidence of adverse drug reactions (ADR) between trimethoprim-sulfamethoxazole and dapsone might be explained, in part, by differences in the inherent toxicity of the hydroxylamine metabolites of sulfamethoxazole and dapsone."	( Comparison of the in vitro cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone. Bellevue, FH; Reilly, TP; Svensson, CK; Woster, PM, 1998)	0.76
"Treatment with sulfonamide antibiotics in HIV-infected patients is associated with a high incidence (> 40%) of adverse drug events, including severe hypersensitivity reactions."	( Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole. Hess, DA; Madrenas, J; Puvanesasingham, R; Rieder, MJ; Sisson, ME; Suria, H; Wijsman, J, 1999)	0.51
"Hypersensitivity adverse drug reactions are much more common among patients with acquired immunodeficiency syndrome (AIDS) than in the general population."	( Differential toxicity of reactive metabolites of clindamycin and sulfonamides in HIV-infected cells: influence of HIV infection on clindamycin toxicity in vitro. Dekaban, GA; Rieder, MJ; Wijsman, JA, 2005)	0.33
" Electron beam treatment could be an effective and safe method for the removal of antibiotic compounds."	( Degradation and toxicity assessment of sulfamethoxazole and chlortetracycline using electron beam, ozone and UV. Kim, HY; Kim, SD; Kim, TH; Lee, M; Lim, SJ; Yu, S, 2012)	0.65
"Drug hypersensitivity reactions (DHRs) are rare but potentially fatal adverse drug reactions (ADRs)."	( The predictive value of the in vitro platelet toxicity assay (iPTA) for the diagnosis of hypersensitivity reactions to sulfonamides. Elzagallaai, AA; Koren, G; Rieder, MJ, 2013)	0.39
" The results indicate that the oxidative treatment (O3 or UV/H2O2) of Bisphenol A, Metoprolol, Sulfamethoxazole or Ciprofloxacin in waste water did not result in toxic oxidation by-products, whereas the UV/H2O2 treatment of Bisphenol A and Ciprofloxacin in pure water resulted in by-products with cytotoxic but no estrogenic effects after 60min."	( Toxicity of the micropollutants Bisphenol A, Ciprofloxacin, Metoprolol and Sulfamethoxazole in water samples before and after the oxidative treatment. Bester, K; Boergers, A; Richard, J; Tuerk, J; Vom Eyser, C, )	0.58
" Of particular concern is the occurrence of pharmaceutical mixtures, which may lead to increased adverse effects compared to individual compounds."	( Individual and mixture toxicity of pharmaceuticals naproxen, carbamazepine, and sulfamethoxazole to Australian striped marsh frog tadpoles (Limnodynastes peronii). Cameron, MC; Lanctôt, CM; Melvin, SD, 2014)	0.63
" A variation of the algae growth was observed, which was due to the combination of generation of toxic intermediates (i."	( Determination and toxicity evaluation of the generated products in sulfamethoxazole degradation by UV/CoFe(2)O(4)/TiO(2). Chu, W; Gong, H, 2016)	0.67
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" At a low concentration of toxic substances, a hormetic stimulating effect occurs, while an inhibitory effect occurs at higher concentrations."	( Elimination of the hormesis phenomenon by the use of synthetic sea water in a toxicity test towards Aliivibrio fischeri. Drzymała, J; Kalka, J, 2020)	0.56
" Therefore, LYC dietary supplement possesses liver protective function against exogenous toxic compounds like SMZ, making LYC a functional aquatic feed ingredient for aquiculture."	( Lycopene alleviates sulfamethoxazole-induced hepatotoxicity in grass carp ( Guo, M; Mu, M; Wang, Y; Xing, M; Yu, H; Zhao, H, 2020)	0.88
" However, most studies only focus on individual toxic effects, rather combined."	( Environmentally relevant concentration of cypermethrin or/and sulfamethoxazole induce neurotoxicity of grass carp: Involvement of blood-brain barrier, oxidative stress and apoptosis. Guo, M; Liu, Y; Wang, Y; Xing, M; Yu, H; Zhao, H, 2021)	0.86
" Herein, nZVI was modified by a β-cyclodextrin polymer (β-CDP), which is considered an environmentally safe and inexpensive adsorbent of contaminants."	( Enhanced degradation of sulfamethoxazole by a modified nano zero-valent iron with a β-cyclodextrin polymer: Mechanism and toxicity evaluation. Černík, M; Dionysiou, DD; Krawczyk, K; Nguyen, NHA; Padil, VVT; Řezanka, M; Ševců, A; Silvestri, D; Wacławek, S; Łukowiec, D, 2022)	1.03
"This substance has toxic effects on various aquatic organisms."	( Toxic effects and molecular mechanisms of sulfamethoxazole on Scenedesmus obliquus. Li, J; Xie, Y; Xu, D, 2022)	0.99
" The main scope of this review is to fill the void of information on the knowledge on the African occurrence of selected PCs in environmental matrices in comparison with those outside Africa and their respective toxic actions on both aquatic and non-aquatic biota through ecotoxicity bioassays."	( Occurrence, detection and ecotoxicity studies of selected pharmaceuticals in aqueous ecosystems- a systematic appraisal. Oladoye, PO; Olatunji, OS; Oluwole, AO; Omotola, EO, 2022)	0.72
" To study the SMX's brain toxic effects and the related mechanisms, we exposed zebrafish embryos to SMX at different concentrations (0 ppm, 1 ppm, 25 ppm, 100 ppm and 250 ppm) and found that high concentration (250 ppm) of SMX would not only caused an abnormal in malformation rate, hatching rate, body length and survival rate of zebrafish embryos, but also lead to brain oedema."	( Sulfamethoxazole induces brain capillaries toxicity in zebrafish by up-regulation of VEGF and chemokine signalling. Chen, J; Luo, L; Xu, Y, 2022)	2.16
" This study investigated the reporting risk of AKI associated with antibacterials using the individual case safety reports (ICSRs) submitted to the Food and Drug Administration Adverse Event Reporting System (FAERS) database."	( Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system. Chinzowu, T; Chyou, TY; Nishtala, PS, 2022)	0.72
"75 mg/L, no observed adverse effect level derived from its reproductive toxicity) and SMX (0."	( Co-contaminants of ethinylestradiol and sulfamethoxazole in groundwater exacerbate ecotoxicity and ecological risk and compromise the energy budget of C. elegans. Chang, CH; How, CM; Huang, CW; Kuo, YH; Liao, VH; Yen, PL; Yu, CW, 2023)	1.18
" The data also provide evidence that accumulation of toxic reactive metabolites could be an important component in the cascade of events leading to the development of DHRs in CF patients."	( Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk. Abuzgaia, AM; Elzagallaai, AA; Mullowney, T; Rieder, MJ, 2023)	0.91
" magna both in vivo and in vitro, which explained the adverse effects of SMZ on locomotor ability and lipid metabolism at the molecular levels."	( Adverse effects of sulfamethoxazole on locomotor behavior and lipid metabolism by inhibiting acetylcholinesterase and lipase in Daphnia magna. Gu, J; Guo, X; Liu, F; Ni, Z; Tang, T; Xiu, W; Yan, M; Zhang, Y, 2023)	1.24
" The SMX and PS-NPs co-exposure decreased intestinal microbiota diversity compared to the PS-NPs, and caused more adverse effect on the intestinal microbiota composition and intestinal damage compared to the SMX, indicating that PS-NPs might enhance the toxicity of SMX on the medaka intestine."	( Nanoplastics enhance the intestinal damage and genotoxicity of sulfamethoxazole to medaka juveniles (Oryzias melastigma) in coastal environment. Han, C; Li, X; Lu, X; Luo, J, 2023)	1.15
"Sulfamethoxazole (SMZ) and zinc (Zn) are widespread harmful materials in aquatic ecosystems and cause toxic effects to aquatic animals under their individual exposure."	( Zinc attenuates sulfamethoxazole-induced lipotoxicity by reversing sulfamethoxazole-induced mitochondrial dysfunction and lysosome impairment in a freshwater teleost. Chen, G; Luo, Z; Lv, W; Wei, X; Xu, Y; Zhang, D; Zheng, H, 2023)	2.7

Excerpt	Reference	Relevance
" It is suggested that more emphasis be given to general pharmacokinetic principles in drug information programs."	( Doses and dosage intervals of drugs--clinical practice and pharmacokinetic principles. Boëthius, G; Sjöqvist, F, 1978)	0.26
" coli and pharmacokinetic studies presented, the suggested dose for the combination 2-sulfa-4,5-dimethyl-oxazole/TMP seems to be sufficient, the dosage regimen is correct, whereas the amount of 3-sulfa-5-methyl-isoxazole (SMZ) in the dose proposed for the combination SMZ/TMP seems to be unreasonably high and the dosage scheme is incorrect."	( [Studies on synergistic behaviour and pharmacokinetics of the combination sulfonamide/trimethoprim. IV. A comparative study on potentiating the trimethoprim effect by various sulfonamides and critical observations on its dosing (author's transl)]. Seydel, JK; Wempe, E, 1977)	0.26
"In this review the pharmacokinetic properties of trimethoprim (TMP) and TMP/sulphonamide combinations are discussed."	( The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues. Reeves, DS; Wilkinson, PJ, 1979)	0.26
" In renal impairment although the serum half-life (t1/2) of both active and total SDZ remains similar to that of TMP, the t1/2 of total SMZ becomes several times higher than the t1/2 of TMP."	( Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function. Anstad, U; Bergan, T; Brodwall, EK; Vik-Mo, H, 1979)	0.26
" The pharmacokinetic parameters were derived from a simultaneous curve fitting of the Bateman function on the basis of the multiple dose equation."	( Steady-state pharmacokinetics of sulfamethoxazole and trimethorprim in man after rectal application. Haase, W; Liedtke, R, 1979)	0.54
" Despite its in vitro and pharmacokinetic advantages, co-trimoxazole was not any more efficient than any other durg or no therapy in the treatment of salmonella gastroenteritis; it seems to have a role, however, in the treatment of typhoid fever and may be life-saving in patients infected with ampicillin- and chloramphenical-resistant strains."	( Pharmacokinetics and efficacy of trimethoprim-sulfamethoxazole in the treatment of gastroenteritis in children. Marks, MI, 1975)	0.51
" Blood and urine samples were obtained, concentrations of TMP, SMZ, and its metabolite N4-acetyl SMZ were measured by HPLC and pharmacokinetic analyses were performed."	( Pharmacokinetics of sulfamethoxazole and trimethoprim in Mexicans: bioequivalence of two oral formulations (URO-TS D and Bactrim F). Castañeda-Hernández, G; Chávez, F; Flores-Murrieta, FJ; Herrera, JE; Hong, E; Menéndez, JC, 1990)	0.6
" Plasma and dialysate concentrations were monitored for 1 exchange after administration of a single oral or intraperitoneal dose of co-trimoxazole, and were fitted by a pharmacokinetic model that took into account the equilibrium nature of CAPD by including return from the peritoneum in oral studies and from the plasma in intraperitoneal studies."	( Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics. O'Flaherty, EJ; Pesce, AJ; Singh, S; Svirbely, JE, 1989)	0.28
" It is concluded that there is no consistent pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole in NIDDM patients."	( Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole. Christenson, I; Emilsson, H; Gunnarsson, R; Ostman, J; Sjöberg, S; Thunberg, E; Wiholm, BE, )	0.13
"The objective of this study was to determine both the pharmacokinetic parameters and the bioavailability of a newly developed trimethoprim/sulfamethoxazole preparation (cotrimoxazole, Kepinol forte, 160 mg of trimethoprim/800 mg of sulfamethoxazole) in comparison with a reference preparation customary in trade and registered according to the AMG 1976, after single oral administration."	( [Studies of the pharmacokinetics and bioavailability of a new trimethoprim/sulfamethoxazole preparation in healthy volunteers]. Hutt, V; Jaeger, H; Klingmann, I; Nieder, M; Pabst, GU; Salama, Z, 1988)	0.71
" Quinolones and the calcium salt of fosfomycin are useful but do not have an ideal pharmacokinetic profile."	( The microbiological and pharmacokinetic profile of an antibacterial agent useful for the single-dose therapy of urinary tract infection. Greenwood, D; Slack, R, 1987)	0.27
" The changes observed in the pharmacokinetic parameters of SMZ after tolbutamide treatment is due to the induction of liver N-acetyltransferase activity."	( Effect of tolbutamide treatment on the pharmacokinetics of intravenously administered sulphamethoxazole in rabbits. Garg, SK; Ghosh, SS; Mathur, VS, 1987)	0.27
" Trimethoprim was found in higher concentrations in the sputum than in the blood, although there were wide and significant variations in individual patient's sputum pharmacokinetic profiles."	( Trimethoprim alone compared to co-trimoxazole in lower respiratory infections: pharmacokinetics and clinical effectiveness. Brumfitt, W; Hamilton-Miller, JM; Havard, CW; Tansley, H, 1985)	0.27
" Following oral administration of a single dose, the pharmacokinetic parameters of SMZ and its N4-acetylated metabolite (N4SMZ) were similar in both groups."	( Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. Advenier, C; Cordonnier, P; Ducreuzet, C; Gobert, C; Lajoie, D; Pays, M; Varoquaux, O, 1985)	0.27
" The half-life of TMP and SMXA determined by model independent methods were 33."	( Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. Blevins, RB; Halstenson, CE; Matzke, GR; Salem, NG, 1984)	0.64
" Factors contributing to the transport of solutes through the peritoneal membrane are discussed and the literature concerning the pharmacokinetic aspects of CAPD is reviewed."	( Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review. Janknegt, R; Koks, CH, 1984)	0.27
" Pharmacokinetic analysis was based upon "one compartment model"."	( Pharmacokinetic analysis of the level of sulfonamide-trimethoprim combination in calves. Duda, M; Roliński, Z, )	0.13
" The pharmacokinetic analysis showed a plasma elimination half-life in the terminal phase of 10."	( Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients. Naber, K; Vergin, H; Weigand, W, 1981)	0.26
" Pharmacokinetic studies in dogs show that trimethoprim readily reaches therapeutic levels in prostatic fluid, yet clinical studies indicate that only about one-third of men with chronic bacterial prostatitis are cured of infection after prolonged therapy with trimethoprim-sulfamethoxazole."	( Prostatitis: review of pharmacokinetics and therapy. Meares, EM, )	0.31
"The pharmacokinetic behaviour of sulphamethoxazole and trimethoprim was studied after combined intravenous (i."	( Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. Lashev, LD; Mihailov, R, 1994)	0.29
" Comparison of the pharmacokinetic parameters in this study with those of our previous findings indicates that the elimination of trimethoprim-sulfamethoxazole follows a first-order process within the dose ranges assessed."	( Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Laizure, SC; Sanders, PL; Stein, DS; Stevens, RC, 1993)	0.71
"The objective of this study was to assess both pharmacokinetic properties and bioavailability of a newly developed cotrimoxazole preparation (Bioprim tablets, 80 mg of trimethoprim/400 mg sulfamethoxazole), in comparison with a reference preparation commercially available (Bactrim tablets, 80 mg of trimethoprim/400 mg of sulfamethoxazole)."	( Comparative pharmacokinetics and bioavailability of two cotrimoxazole preparations. Brzaković, B; Galetin, A; Miljković, B; Pokrajac, M; Simić, D, 1998)	0.49
" Thus, not only drug monitoring but also pharmacokinetic investigations from blood plasma have become possible without further sample pretreatment."	( Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). Kunkel, A; Wätzig, H, 1999)	0.3
" The half-life (t(1/2)) was significantly shorter in the morning (11."	( Circadian changes in pharmacokinetics of sulfamethoxazole administered orally to rabbits. Choi, JS; Jung, EJ, 2001)	0.58
" After oral administration, some pharmacokinetic parameters of sulfamethoxazole were significantly different in diabetes mellitus."	( Pharmacokinetic changes of oral sulfamethoxazole in rabbits with diabetes mellitus induced by alloxan. Choi, BC; Choi, JS, )	0.65
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population."	( Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. Feng, WL; Gao, F; Ge, RL; Guan, W; Li, XY; Li, ZQ, 2009)	0.82
"0 software to get the related pharmacokinetic parameters."	( [Pharmacokinetics of sulfamethoxazole in healthy Han volunteers living at plain and in native Han and Tibetan healthy volunteers living at high altitude]. Li, XY; Li, YP; Liu, YN; Yuan, M; Zhu, JB, 2011)	0.69
"The study was aimed at determination of pharmacokinetic parameters of a previously synthesized salicylidine-sulfamethoxazole-Zn(II) monohydrate in normal humans."	( Pharmacokinetic study of a new derivative of sulfamethoxazole. Iqbal, MS; Khan, AH; Saeed, M; Sher, M, 2012)	0.85
"To evaluate the potential for pharmacokinetic interactions between MMX mesalamine and amoxicillin, ciprofloxacin extended release (XR), metronidazole, or sulfamethoxazole in four open-label, randomized, placebo-controlled, two-period crossover studies."	( Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. Barrett, K; Corcoran, M; Inglis, S; Martin, P; Pierce, D; Preston, P; Thompson, TN; Willsie, SK, 2014)	0.81
" Sulfamethoxazole exposure increased by a statistically significant amount when coadministered with MMX mesalamine; however, increased exposure (by 12% in Cmax at steady state; by 15% in AUC at steady state) was not considered clinically significant, as the 90% CIs for each point estimate fell entirely within the predefined equivalence range."	( Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. Barrett, K; Corcoran, M; Inglis, S; Martin, P; Pierce, D; Preston, P; Thompson, TN; Willsie, SK, 2014)	1.52
" Since mefloquine is being considered as a replacement for sulfadoxine/pyrimethamine in this vulnerable population, an investigation on the pharmacokinetic interactions of mefloquine, sulfamethoxazole and trimethoprim in pregnant, HIV-infected women was performed."	( Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. Desai, M; González, R; Green, M; Kariuki, S; Katana, A; Menendez, C; Otieno, K; Ouma, P; Slutsker, L; ter Kuile, F, 2016)	0.88
" Non-compartmental methods using a naïve-pooled data approach were used to determine mefloquine pharmacokinetic parameters."	( Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. Desai, M; González, R; Green, M; Kariuki, S; Katana, A; Menendez, C; Otieno, K; Ouma, P; Slutsker, L; ter Kuile, F, 2016)	0.69
" However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients."	( Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016)	0.72
"The present study was carried out to demonstrate novel use of pharmacokinetic approaches to characterize drug behaviors/movements in the vegetables with implications to food safety."	( Assessment of veterinary drugs in plants using pharmacokinetic approaches: The absorption, distribution and elimination of tetracycline and sulfamethoxazole in ephemeral vegetables. Chen, HR; Chou, CC; Loh, SH; Rairat, T; Vickroy, TW; Wu, YC, 2017)	0.66
" The method was validated and applied to compare the pharmacokinetic profiles of the analytes in serum of Alpha-naphthylisothiocyanate (ANIT)-induced cholestasis and control rats after oral administration of XYLDF."	( Pharmacokinetic study of seven bioactive components of Xiaoyan Lidan Formula in cholestatic and control rats using UPLC-MS/MS. Huang, T; Lin, C; Liu, F; Wang, M; Yao, Y; Zhang, K; Zhu, C, 2021)	0.62

Excerpt	Reference	Relevance
"In a double blind, randomized study, sulfamethoxazole was compared alone and in combination with trimethoprim as commonly used in therapeutic regimes for the treatment of uncomplicated acute urinary tract infections in out-patients."	( Comparison of sulfamethoxazole alone and combined with trimethoprim in urinary tract infections. Bergan, T; Skjerven, O, 1979)	0.89
"Trimethoprim, in combination with sulfadiazine or sulfamethoxazole was administered orally for 7 to 14 days to 84 dogs with urinary tract infections (UTI)."	( Trimethoprim in combination with a sulfonamide for oral treatment of canine urinary tract infections. Ling, GV; Ruby, AL, 1979)	0.51
" Significantly, NF combined with TMP-SMZ proved effective against isolates with decreased susceptibility to TMP-SMZ as well."	( In vitro additive effect of nitrofurantoin combined with trimethoprim-sulfamethoxazole against Serratia marcescens. Fukushima, PI; Traub, WH, 1979)	0.49
" On the basis of literature data six sulphonamides, sulphadiazine, sulphachloropyridazine, sulphamethoxazole, sulphaisodimidine, sulphamerazine and sulphamethomidine appeared particularly suitable for combination with trimethoprim."	( Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim. Bergan, T; Ekström, B; Forsgren, U; Ortengren, B, 1979)	0.26
"We report the excellent therapeutic response obtained with amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of 15 patients with actinomycotic mycetoma who had a poor response to the traditional pharmacologic agents and/or in whom important organs such as lungs, spinal cord, and bone were involved."	( Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. Gonzalez, J; Ocampo, J; Sauceda, E; Welsh, O, 1987)	0.74
" Sulfamoxole (SMO), Sulfadiazine (SDZ) and Sulfadimidine (SDD) in combination with trimethoprim (TMP) were studied in 12 healthy volunteers."	( Comparative pharmacokinetic study of four different sulfonamides in combination with trimethoprim in human volunteers. Garg, SK; Ghosh, SS; Mathur, VS, 1986)	0.27
"Haemophilus influenzae is only moderately susceptible to erythromycin but previous studies in vitro and in vivo have shown that it is fully susceptible when erythromycin is combined with sulphonamides."	( Roxithromycin alone and in combination with sulphamethoxazole against Haemophilus influenzae. Bourget, C; Lapointe, JR; Lavallée, C; Meilleur, R, 1987)	0.27
"Experience with trimethoprim-sulfamethoxazole (TMP-SMZ) alone or in combination with other agents in the treatment of immunocompromised patients other than those with Pneumocystis carinii pneumonitis and the acquired immunodeficiency syndrome is reviewed."	( Use of trimethoprim-sulfamethoxazole singly and in combination with other antibiotics in immunocompromised patients. Hindler, J; Young, LS, )	0.75
"We explored the antibacterial activity of phosphanilic acid (P), an analog of sulfanilic acid, alone and in combination with trimethoprim (T; TP, 1:5) with sulfamethoxazole (S) and co-trimoxazole, the combination of this sulfonamide with trimethoprim (TS, 1:5) as the reference."	( Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim. Buck, RE; Chisholm, DR; Leitner, F; Misiek, M; Price, KE; Pursiano, TA; Tsai, YH, 1985)	0.47
"A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination co-trimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim)."	( A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. Bagnato, A; Colombo, F; Colombo, ML; Dei, D; Donno, L; Ginesu, F; Ortu, AR; Peona, V, 1984)	0.27
" In this study, trimethoprim combined with sulphadiazine in the ratio 1:4 was compared when combined with sulphamethoxazole in the ratio 1:20."	( Susceptibility testing to trimethoprim alone and combined with sulphonamides. Dornbusch, K; Gezelius, L, 1980)	0.26
" When PS-15 was administered in combination with sulfamethoxazole to healthy Saimiri sciureus monkeys, the serum antimalarial activity was considerably greater than that observed in monkeys that received PS-15 alone."	( The activity of PS-15 in combination with sulfamethoxazole. Rieckmann, KH; Yeo, AE, 1994)	0.81
"In MRC-5 cell cultures, the efficacy of the acyclic nucleoside ganciclovir (GCV) against human cytomegalovirus (CMV) was unaffected when combined with either amphotericin B (AMP B), ketoconazole (KCZ), dapsone (DAP), or trimethoprim/sulfamethoxazole (TMP/SMX)."	( Efficacy of ganciclovir in combination with other antimicrobial agents against cytomegalovirus in vitro and in vivo. Fraser-Smith, EB; Freitas, VR; Matthews, TR, 1993)	0.47
"To evaluate the effect of allicin alone or combined with SMZco on murine toxoplasmosis by a specific, rapid, and sensitive PCR technique."	( [PCR in evaluating the effect of allicin and its combination with SMZco on murine toxoplamosis]. Liu, PM; Shan, LY; Yang, XZ, 2003)	0.32
"When SMZco is used in combination with allicin, a much higher efficacy is received in the treatment of acute murine toxoplasmosis."	( [PCR in evaluating the effect of allicin and its combination with SMZco on murine toxoplamosis]. Liu, PM; Shan, LY; Yang, XZ, 2003)	0.32
" We studied the activities of the combination of CAS and SMX against 31 Aspergillus isolates and compared them with that of SMX combined with amphotericin B (AMB) or itraconazole (ITC)."	( In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Osherov, N; Shadkchan, Y; Shalit, I; Yekutiel, A, 2004)	0.58
"A novel, rapid and continuous on-line concentration approach based on dynamic pH junction for the analysis of trimethoprim (TMP) and sulfamethoxazole (SMZ) by microfluidic capillary electrophoresis (CE) combined with flow injection analysis is developed in this paper."	( Continuous on-line concentration based on dynamic pH junction for trimethoprim and sulfamethoxazole by microfluidic capillary electrophoresis combined with flow injection analysis system. Chen, H; Chen, X; Fan, L; Hu, Z; Liu, L, 2005)	0.76
" Specific growth patterns were indicative of additive (indifferent), synergistic, or antagonistic effects of the drug combination used."	( Technique for determining the bactericidal effect of drug combinations. Fodor, G; Lorian, V, 1974)	0.25
" According to this concept, even chemically inert drugs can stimulate T cells because certain drugs interact in a direct way with T-cell receptors (TCR) and possibly major histocompatibility complex molecules without the need for metabolism and covalent binding to a carrier."	( Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Depta, JP; Lüthi, M; Pichler, WJ; Schmid, DA, 2006)	0.33
" aeruginosa are investigated for drug-drug interactions in vitro."	( Activity of Chitosans in combination with antibiotics in Pseudomonas aeruginosa. Lim, CS; Sakharkar, KR; Sakharkar, MK; Tin, S, 2009)	0.35
" We evaluated the in vitro activity of JPC 2067 alone and in combination with sulfamethoxazole (SMX) against a panel of nocardia isolates."	( In vitro activity of JPC 2067 alone and in combination with sulfamethoxazole against nocardia species. Cynamon, M; Mookherjee, S; Shoen, C, 2012)	0.85
"To investigate the extent to which clinicians avoid well-established drug-drug interactions associated with warfarin."	( Adherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish Register Study. Andersson, ML; Lindh, JD; Mannheimer, B, 2014)	0.4
" The aim of this study was to investigate the repurposing of escitalopram oxalate and clonazepam drugs individually, and in combination with the antibiotics ciprofloxacin and sulfamethoxazole-trimethoprim, to treat multidrug-resistant (MDR) microorganisms and to evaluate the potential chemical nuclease activity."	( Repurposing of escitalopram oxalate and clonazepam in combination with ciprofloxacin and sulfamethoxazole-trimethoprim for treatment of multidrug-resistant microorganisms and evaluation of the cleavage capacity of plasmid DNA. Bottega, A; Coelho, SS; Foletto, VS; Hörner, R; Lorenzoni, VV; Machado, CS; Mainardi, A; Rampelotto, RF; Rosa, TFD; Serafin, MB, 2021)	1.04
" In this study, a new method for the microplastics quantitatively and qualitatively analysis by two-phase (ethyl acetate-water) system combined with confocal Raman spectroscopy was developed."	( Separation of false-positive microplastics and analysis of microplastics via a two-phase system combined with confocal Raman spectroscopy. Chang, M; Dai, Z; Hong, P; Hu, J; Jiang, WY; Li, C; Liang, YQ; Liao, Y; Liu, Y; Lu, Z; Qian, ZJ; Ren, L; Sun, R; Sun, S; Yang, J; Zhang, Y; Zhou, C, 2022)	0.72

Excerpt	Reference	Relevance
" The drug is well absorbed in children with gastroenteritis due to a variety of causes and is distributed, excreted and metabolized in a manner similar to that seen in normal adult volunteers."	( Pharmacokinetics and efficacy of trimethoprim-sulfamethoxazole in the treatment of gastroenteritis in children. Marks, MI, 1975)	0.51
" An influence of the liver disease on the absorption rate via alteration of the biliary conditions is envisaged as a possible explanation."	( [Comparison of pharmacokinetics of the combination trimethoprim and sulfamethoxazole in patients with liver diseases and healthy persons]. Rieder, VJ; Schwartz, DE, 1975)	0.49
" The in vitro dissolution and in vivo bioavailability of two commercial trimethoprim-sulfadiazine-sulfamethoxazole tablets (A and B) were studied."	( [Studies on the dissolution and bioavailability of trimethoprim-sulfadiazine-sulfamethoxazole tablets]. Mao, FF; Shao, J; Tu, XD, 1992)	0.73
" The systemic bioavailability was 19."	( Kinetic disposition, systemic bioavailability, tissue levels and acetylation of some sulphonamides in goats. Atef, M; Issa, M; Ramadan, A; Youssef, SA, )	0.13
"In vitro release, stability as well as bioavailability of sulphamethoxazole (SMZ) suppositories were investigated using solid dispersion techniques for surfactant incorporation."	( Effect of surfactant incorporation techniques on sulphamethoxazole suppository formulations. Abd el-Alim, HA; Abd el-Gawad, AH; el-Din, EZ, 1988)	0.27
"The objective of this study was to determine both the pharmacokinetic parameters and the bioavailability of a newly developed trimethoprim/sulfamethoxazole preparation (cotrimoxazole, Kepinol forte, 160 mg of trimethoprim/800 mg of sulfamethoxazole) in comparison with a reference preparation customary in trade and registered according to the AMG 1976, after single oral administration."	( [Studies of the pharmacokinetics and bioavailability of a new trimethoprim/sulfamethoxazole preparation in healthy volunteers]. Hutt, V; Jaeger, H; Klingmann, I; Nieder, M; Pabst, GU; Salama, Z, 1988)	0.71
" It is suggested that the bioavailability and thereby, the antileukaemic effect) during maintenance therapy of ALL of 6-MP may be decreased by the co-administration of CTX."	( The effect of cotrimoxazole on the absorption of orally administered 6-mercaptopurine in the rat. Aherne, GW; Burton, NK, 1986)	0.27
"The relative bioavailability of a co-trimoxazole suspension manufactured by VEB Berlin-Chemie (B); Belocid-Suspension was compared with a widespread used suspension (V) in healthy male students (22-29 ys."	( [The relative bioavailability of co-trimoxazole suspensions]. Günther, C; Traeger, A; Truckenbrodt, J, 1987)	0.27
"An in vitro study was made of the bactericidal activity against Escherichia coli of fosfomycin trometamol, a new fosfomycin salt characterized by high bioavailability in relation to the pH, inoculum and culture medium, the latter being nutrient broth or human urine."	( Influence of pH, inoculum and media on the in vitro bactericidal activity of fosfomycin trometamol, norfloxacin and cotrimoxazole. Albini, E; Belluco, G; Marca, G, 1986)	0.27
" The agent must therefore be well absorbed and have slow renal excretion."	( The microbiological and pharmacokinetic profile of an antibacterial agent useful for the single-dose therapy of urinary tract infection. Greenwood, D; Slack, R, 1987)	0.27
" Either the necessity to optimize bioavailability because of the underlying seriousness of disease or a desire to avoid other drugs that may be responsible for adverse reactions or hypersensitivity should direct the clinician to administer an intravenous preparation."	( Use of trimethoprim-sulfamethoxazole in pediatric infections: relative merits of intravenous administration. Overturf, GD, )	0.45
" P was well absorbed parenterally but not orally in mice."	( Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim. Buck, RE; Chisholm, DR; Leitner, F; Misiek, M; Price, KE; Pursiano, TA; Tsai, YH, 1985)	0.27
" The oral bioavailability of SMZ and TMP was ."	( Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens. Castells, I; Queralt, J, 1985)	0.59
" It also showed that this tendency was noticeable in dose elevation at fixed injection volume and became more significant for drugs with a smaller absorption rate and/or a larger elimination rate."	( Studies on the absorption of practically water-insoluble drugs following injection VII: plasma concentration after different subcutaneous doses of a drug in aqueous suspension in rats. Hirano, K; Yamada, H, 1983)	0.27
" In addition, the absorption rate constants (j) of the mouse and rabbit were close to that of the rat when the drug concentration (C0) in the suspension and the injection volume (V0) were fixed."	( Studies on the absorption of practically water-insoluble drugs following injection VIII: comparison of the subcutaneous absorption rates from aqueous suspensions in the mouse, rat, and rabbit. Hirano, K; Yamada, H, 1983)	0.27
" The bioavailability was 81% for sulphamethoxazole and 41% for trimethoprim."	( Pharmacokinetics of sulphamethoxazole and trimethoprim administered intravenously and orally to Japanese quails. Lashev, LD; Mihailov, R, 1994)	0.29
"5 h) and the bioavailability was only 12."	( Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model. Maas, R; Rátz, V; Semjén, G; van Miert, AS; Witkamp, RF, 1995)	0.29
" Neither formulation could produce sufficient blood concentration of the drug, though the bioavailability of SMX for the coated formulation was higher than that for the uncoated formulation."	( Bioavailability of ruminally protected sulfamethoxazole after oral administration in ruminating calves. Hayama, T; Nishida, Y; Oda, K; Takahashi, Y, 1997)	0.57
"The objective of this study was to assess both pharmacokinetic properties and bioavailability of a newly developed cotrimoxazole preparation (Bioprim tablets, 80 mg of trimethoprim/400 mg sulfamethoxazole), in comparison with a reference preparation commercially available (Bactrim tablets, 80 mg of trimethoprim/400 mg of sulfamethoxazole)."	( Comparative pharmacokinetics and bioavailability of two cotrimoxazole preparations. Brzaković, B; Galetin, A; Miljković, B; Pokrajac, M; Simić, D, 1998)	0.49
" A poorly absorbed drug if effective in treating bacterial diarrhea has pharmacologic and safety advantages over the existing drugs."	( Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. de la Cabada, FJ; DuPont, HL; DuPont, MW; Ericsson, CD; Jiang, ZD; Mathewson, JJ; Mosavi, A; Palazzini, E, )	0.13
"Many workers have attempted to determine the bioavailability of pharmaceutical formulations, which is important to assure the efficacy and safety of medications."	( Comparative bioavailability of sulfamethoxazole in co-trimoxazole suspensions containing different thickness agents. Bentley, MV; Lara, EH; Marchetti, JM; Shuhama, IK, 1999)	0.59
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" Furthermore, current water quality monitoring does not differentiate between soluble and colloidal phases in water samples, hindering our understanding of the bioavailability and bioaccumulation of pharmaceuticals in aquatic organisms."	( Colloids as a sink for certain pharmaceuticals in the aquatic environment. Maskaoui, K; Zhou, JL, 2010)	0.36
" Such strong pharmaceutical/colloid interactions may provide a long-term storage of pharmaceuticals, hence, increasing their persistence while reducing their bioavailability in the environment."	( Colloids as a sink for certain pharmaceuticals in the aquatic environment. Maskaoui, K; Zhou, JL, 2010)	0.36
" As aquatic colloids are abundant, ubiquitous, and highly powerful sorbents, they are expected to influence the bioavailability and bioaccumulation of such chemicals by aquatic organisms."	( Colloids as a sink for certain pharmaceuticals in the aquatic environment. Maskaoui, K; Zhou, JL, 2010)	0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" The formulation, that provided delivery of active material near to the target value in six healthy volunteers and in vivo tests, clearly revealed that the bioavailability of active material was found to be enhanced by preparing ternary mixtures."	( Enhancement of dissolution rate and bioavailability of sulfamethoxazole by complexation with β-cyclodextrin. Erkin, J; Ozdemir, N, 2012)	0.63
" Toxicity characteristic leaching experiments confirmed that the mobility and bioavailability of SMX in biochar-amended soils were lower than that of unamended soils."	( Adsorption of sulfamethoxazole on biochar and its impact on reclaimed water irrigation. Cao, X; Chen, H; Gao, B; Inyang, M; Jiang, L; Li, H; Xue, Y; Yang, L; Yao, Y; Zimmerman, AR, 2012)	0.74
" These observations are useful for producing designer biochars as engineered sorbents to reduce the bioavailability of antibiotics and/or predict the fate of sulfonamides in biochar-amended soils."	( Sorption of antibiotic sulfamethoxazole varies with biochars produced at different temperatures. Herbert, S; Wang, Z; Xing, B; Zhao, J; Zheng, H, 2013)	0.7
" These observations provide important information on the use of biochars as engineered sorbents for environmental applications, such as reducing the bioavailability of antibiotics and/or predicting the fate of sulfonamides in biochar-amended soils."	( Characterisation of agricultural waste-derived biochars and their sorption potential for sulfamethoxazole in pasture soil: a spectroscopic investigation. Sarmah, AK; Srinivasan, P, 2015)	0.64
"The interaction between biochar (BC) and antibiotics with the presence of low molecular weight organic acids (LMWOAs) is largely unknown, although it is crucial for understanding the role of BC in reducing the bioavailability of antibiotics in rhizosphere."	( Impact of low molecular weight organic acids (LMWOAs) on biochar micropores and sorption properties for sulfamethoxazole. Bao, Q; Lian, F; Liu, Z; Song, Z; Sun, B; Zhu, L, 2016)	0.65
" Moreover, shifts in the use of agents with high bioavailability and those approved for high-dose regimens were observed."	( Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. Shibayama, K; Tsutsui, A; Yahara, K, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" To date, little is known about the role of SPW in regard to the bioavailability of antibiotics for plant."	( Insight into dynamics and bioavailability of antibiotics in paddy soils by in situ soil moisture sampler. Chen, J; Qiao, X; Tian, R; Uddin, M; Zhu, M, 2020)	0.56
" Bioavailability assessment has gradually attracted more attention in order to provide a more realistic assessment of human health risks."	( Prediction models and major controlling factors of antibiotics bioavailability in hyporheic zone. Cheng, Y; Feng, R; Hu, R; Li, H; Zhang, J; Zhou, M; Zhu, T, 2023)	0.91
" This study aims to determine the bioavailability and bioaccumulation of typical antibiotics sulfamethoxazole (SMX) and roxithromycin (RTM) in zebrafish under environmentally realistic conditions."	( Competitive adsorption and bioaccumulation of sulfamethoxazole and roxithromycin by sediment and zebrafish (Danio rerio) during individual and combined exposure in water. Chen, Y; Li, X; Ren, L; Zhou, JL, 2024)	1.92

Excerpt	Relevance	Reference
"Outpatient prescriptions dispensed to 17,000 individuals in the county of Jämtland, Sweden, have been analyzed with regard to doses and dosage schedules."	( Doses and dosage intervals of drugs--clinical practice and pharmacokinetic principles. Boëthius, G; Sjöqvist, F, 1978)	0.26
" In a daily dosage of 1,600 mg of sulfamethoxazole and 320 mg of trimethoprim orally in combination with 100 to 300 mg of colistimethate parenterally, serum cidal levels at 1:8 or greater were achieved in five of six patients."	( Sulfamethoxazole-trimethoprim-polymyxin therapy of serious multiply drug-resistant Serratia infections. Alford, RH; Leonard, JM; Thomas, FE, 1976)	1.98
" Successful treatment was acheived with administration of trimethoprim plus sulfamethoxazole at a dosage adjusted to the degree of renal failure."	( Trimethoprim with sulfamethoxazole for treatment of infection with Pneumocystis carinii in renal insufficiency. Bourgault, AM; Brewer, NS; Rosenow, EC; Van Scoy, RE, 1978)	0.82
" coli and pharmacokinetic studies presented, the suggested dose for the combination 2-sulfa-4,5-dimethyl-oxazole/TMP seems to be sufficient, the dosage regimen is correct, whereas the amount of 3-sulfa-5-methyl-isoxazole (SMZ) in the dose proposed for the combination SMZ/TMP seems to be unreasonably high and the dosage scheme is incorrect."	( [Studies on synergistic behaviour and pharmacokinetics of the combination sulfonamide/trimethoprim. IV. A comparative study on potentiating the trimethoprim effect by various sulfonamides and critical observations on its dosing (author's transl)]. Seydel, JK; Wempe, E, 1977)	0.26
" The daily dosage of 26."	( Trimethoprim in combination with a sulfonamide for oral treatment of canine urinary tract infections. Ling, GV; Ruby, AL, 1979)	0.26
" Co-trimazine was found to have a greater antibacterial activity than co-trimoxazole and its use at a lower dosage than that of the latter appears warranted."	( Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat. Ritzerfeld, W, 1979)	0.26
"The effects of a twice daily dosage of a combination of 410 mg sulphadiazine + 90 mg trimethoprim (SD + TMP) and 800 mg sulphamethoxazole + 160 mg trimethoprim (SMZ + TMP) were compared in uncomplicated urinary tract infections."	( Double-blind comparison of sulphonamide-trimethoprim combinations in acute uncomplicated urinary tract infections. Bergan, T; Skjerven, O, 1979)	0.26
" Patients with acute urinary tract infections given 400 mg bacampicillin and patients with chronic infections given double that dosage showed equally good results."	( Elimination of bacteria during antibacterial chemotherapy--a neglected parameter of chemotherapy. Helm, EB; Munk, I; Shah, PM; Stille, W, 1979)	0.26
" With the former drug, the result of scrutiny for crystals after dosage until the steady state was negative, whereas crystals of acetylated sulphamethoxazole were detected and verified chemically in two of eight subjects."	( Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 3: Pharmacokinetic characterization of sulphadiazine and sulphamethoxazole given with trimethoprim. Bergan, T; Magni, L; Ortengren, B, 1979)	0.26
" On the basis of the pharmacokinetic properties, dosage schedules are suggested that will give approximately the same plasma levels regardless of renal function."	( Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function. Anstad, U; Bergan, T; Brodwall, EK; Vik-Mo, H, 1979)	0.26
" The knowledge of this fact is of great importance, and should be taken into consideration in the calculation of proper dosage of various drugs in the newborns and infants."	( [Binding capacity of some drugs to plasma proteins of newborns in comparison with adults (author's transl)]. Bozkowa, K; Hofman, H; Piekarczyk, A; Prokopczyk, J; Wańkowicz, B, 1977)	0.26
"The pharmacokinetics of a combination of 800 mg sulfamethoxazole (SMZ) and 160 mg trimethoprim (TMP) were studied in 5 healthy male volunteers after repetitive rectal administration at constant 8-h dosing intervals."	( Steady-state pharmacokinetics of sulfamethoxazole and trimethorprim in man after rectal application. Haase, W; Liedtke, R, 1979)	0.8
" Ampicillin in this dosage was well tolerated except in three children in whom severe urticarial rashes developed and two who had significant diarrhea."	( Typhoid outbreak in Kingston, Ont: experience with high-dose oral ampicillin. Chadwick, P; Hardy, G; Padfield, CJ; Partington, MW, 1977)	0.26
" By the suitable dosage the mortality rate could be reduced considerably."	( [Experimental studies on the effect of the combination sulfamoxole/trimethoprim on the Toxoplasma infection of the mouse (author's transl)]. Maier, W; Piekarski, G, 1976)	0.26
" We used a special dosage schedule for the combination of sulphamethoxazole and trimethoprim in the treatment of patients with normal renal function and with varying degrees of renal impairment."	( Co-trimoxazole in the long-term treatment of pyelonephritis with normal and impaired renal function. Denneberg, T; Ekberg, M; Ericson, C; Hanson, A, 1976)	0.26
" Trimethoprim-sulfamethoxazole (TMP-SMX) was used at one of two dosage levels in the treatment of 20 children with PCP and cancer."	( Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Feldman, S; Hughes, WT; Sanyal, SK, 1975)	0.85
" In the rat these same dosage levels produced urinary inhibitory activity equivalent to 16 to 140 fold that required for 90 per cent urease inhibition."	( Benurestat, a urease inhibitor for the therapy of infected ureolysis. Andersen, JA, 1975)	0.25
" No sigificant difference was observed in the level of tetanus antitoxin produced in subjects who received co-trimoxazole (Septrin) in recommended therapeutic dosage during the first 4 days of the trial from that in subjects who received placebo tablets."	( The effect of co-trimoxazole on antitoxin response to tetanus toxoid. Bye, C; Griffith, AH; Knight, PA; Letley, E, 1975)	0.25
" This value is one of important parameters in a dosage equation by the pharmacokinetics, it showing sigma in an equation, were determined by clinical trial for acute simple cystitis of women."	( The correlation between the clinical effectiveness and ratio of blood concentration to minimum inhibitory concentration of sulfamethoxazole against Escherichia coli isolates. The determination of a parameter in a dosage equation by the pharmacokinetics. Kuraoka, Y; Otaya, H, 1975)	0.46
"The combination trimethoprim-sulfamethoxazole was given in high dosage (four tablets twice daily) for either 2 or 5 days to 20 patients with sinusitis diagnosed on clinical grounds."	( Use of high-dosage trimethoprim-sulfamethoxazole in sinusitis. Whitehead, E, 1975)	0.83
" Cotrimoxazole in the dosage used was well tolerated by all the patients, with very few side-effects."	( Single-dose treatment of gonorrhoea with cotrimoxazole. A report on 1,223 cases. Rahim, G, 1975)	0.25
"Twenty-three patients with typhoid fever diagnosed by blood culture were treated with co-trimoxazole (trimethoprim/sulphamethoxazole, 1 :5) at a dosage of 10 mg trimethoprim/kg/day in two divided daily doses for 10 days."	( Trimethoprim-sulphamethoxazole in the treatment of enteric fever. Ali Omer, MI, 1975)	0.25
" Dosage was based on age."	( The dosage of co-trimoxazole in childhood. Bye, A; Fowle, AS; Hariri, F; Middlemiss, D; Naficy, K, 1975)	0.25
" With the dosage regimen and duration of treatment used in this study cotrimoxazole appears to be superior to cephalexin in the management of acute urinary infections."	( Comparative double-blind study of cephalexin and co-trimoxazole in urinary tract infections. Gower, PE; Tasker, PR, 1976)	0.26
"A simple spectrophotometric method for the determination of 15 sulphonamides in bulk and in dosage forms is described."	( Use of p-benzoquinone for the spectrophotometric determination of certain sulphonamides. Askal, HF; Mohamed, AM; Saleh, GA, 1991)	0.28
" Further studies are indicated in patients to optimize the dosing regimen of trimethoprim-sulfamethoxazole in the treatment of PCP."	( Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. Laizure, SC; Stein, DS; Stevens, RC; Williams, CL, 1991)	0.73
"Each of seven mares was given an intravenous (IV) injection of 40% dimethyl sulfoxide (DMSO) at a dosage of 1 g/kg, over 35 min, immediately followed by a single IV injection of a trimethoprim (TMP) and sulfamethoxazole (SMZ) combination (SMZ 83%, TMP 17%) at a combined dosage of 44 mg/kg (7."	( Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment. Brown, MP; Green, SL; Gronwall, RR; Mayhew, IG; Montieth, G, 1990)	0.74
"Antimicrobial treatment of otitis media, especially drug dosing considerations, is largely empiric, with few reported pharmacologic studies of drug distribution into the middle ear."	( Experimental animal models for studying antimicrobial pharmacokinetics in otitis media. Canafax, DM; Erdmann, GR; Giebink, GS; Juhn, SK; Le, CT; Nonomura, N, 1989)	0.28
" The 200-mg dosage of norfloxacin seemed to cause fewer side effects than the 400-mg dosage."	( Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group. , 1987)	0.51
" Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne."	( On therapeutic approaches to some special types of acne. Rajka, G, 1985)	0.27
" Intravenous TMP-SMX was begun at a dosage of 18 mg/kg/day of trimethoprim."	( Treatment of Pneumocystis carinii pneumonia in patients with AIDS. Hauptman, SP; Wordell, CJ, 1988)	0.27
" The small sample volumes were dictated by the chinchilla model of otitis media and our need to collect multiple samples over a 12-h drug dosing interval."	( High-performance liquid chromatographic analysis of trimethoprim and sulfamethoxazole in microliter volumes of chinchilla middle ear effusion and serum. Canafax, DM; Erdmann, GR; Giebink, GS, 1988)	0.51
" Trimethoprim-sulfamethoxazole dosage was adjusted to maintain serum trimethoprim at 5 to 8 micrograms/mL."	( Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Cowan, R; Nielsen, DM; Ruskin, J; Sattler, FR, 1988)	1
" Toxicity associated with the two standard treatments is rarely life-threatening and may be diminished if the trimethoprim-sulfamethoxazole dosage is modified by pharmacokinetic monitoring and the pentamidine dosage is reduced for nephrotoxicity."	( Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Cowan, R; Nielsen, DM; Ruskin, J; Sattler, FR, 1988)	0.85
" Both dosage forms led to maximum plasma levels of approx."	( [Studies of the pharmacokinetics and bioavailability of a new trimethoprim/sulfamethoxazole preparation in healthy volunteers]. Hutt, V; Jaeger, H; Klingmann, I; Nieder, M; Pabst, GU; Salama, Z, 1988)	0.51
" The carbutamide dosage of 50 mg/kg per day prevented the infection in 90% of animals, whereas tolbutamide in the same dosage permitted infection in 100% of animals."	( Effects of sulfonylurea compounds on Pneumocystis carinii. Hughes, WT; Smith-McCain, BL, 1986)	0.27
" The dosage yielded too high plasma trimethoprim concentrations, while sulfamethoxazole dialysate concentrations were too low."	( Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis. Berden, JH; Hekster, YA; Martea, M; Voets, AJ; Vree, TB, 1987)	0.79
" When the creatinine clearance decreases to less than 30 ml/min, the dosage of trimethoprim-sulfamethoxazole should be adjusted."	( Trimethoprim-sulfamethoxazole. Cockerill, FR; Edson, RS, 1987)	0.86
"3 times as frequent with the "forte" dosage as compared to the 80 mg trimethoprim/400 mg sulfamethoxazole preparation."	( Clinical and practitioners' reports on adverse effects of co-trimoxazole. Auwärter, A; Ding, R; Gutzler, F; Jacubeit, T; Mörike, K; Walter-Sack, I; Weber, E, 1987)	0.49
"025), bismuth subsalicylate (Pepto-Bismol) taken orally at a dosage of as low as 30 ml every half hour for eight doses was shown to be effective in reducing the frequently of episodes of diarrhea."	( Nonantibiotic therapy for travelers' diarrhea. DuPont, HL; Ericsson, CD; Johnson, PC, )	0.13
" A significant dose-response effect was found with both amoxicillin and trimethoprim/sulfamethoxazole."	( Antibiotic-associated gastrointestinal symptoms in general pediatric outpatients. Contardi, R; Flegel, KM; Hutchinson, TA; Kramer, MS; Leduc, DG; Naimark, L, 1985)	0.49
" The present study suggests that both drugs can be given concomitantly without the need for dosage adjustment of theophylline."	( Lack of influence of co-trimoxazole on theophylline pharmacokinetics. Hempenius, J; Holtkamp, AH; Jonkman, JH; Schoenmaker, R; Van der Boon, WJ, 1985)	0.27
" A study of plasma concentrations of TMP, SMZ and N4SMZ during continuous dosing in seven elderly patients treated for urinary or respiratory infections showed that steady state was reached after 3 days of treatment and that plasma drug concentrations were about two to three times higher than those observed after a single dose."	( Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. Advenier, C; Cordonnier, P; Ducreuzet, C; Gobert, C; Lajoie, D; Pays, M; Varoquaux, O, 1985)	0.27
" The dosage used for the new drug was 2 capsules (250 mg trimethoprim + 200 mg sulfamethopyrazine per capsule) the 1st day and 1 capsule for the following 14 days or 2 capsules (trimethoprim 80 mg + sulfamethoxazole 400 mg per capsule) twice daily for 15 days."	( Effect of a new sulfa-trimethoprim combination (trimethoprim-sulfamethopyrazine) in typhoid fever. A double-blind study on 72 adult patients. Piaia, F; Schiraldi, O; Sforza, E, 1985)	0.46
" Leucopenia when it occurred did so soon after transplantation at a time when the function of the renal transplant was poor in relation to the dosage of azathioprine given."	( Co-trimoxazole and azathioprine: a safe combination. Hall, CL, 1974)	0.25
" Statistical analysis showed that the association of leucopenia and trimethoprim-sulphamethoxazole therapy was dependent on the time after the transplantation procedure and was not related to the dosage of immunosuppressive chemotherapy or renal function."	( Leucopenia associated with trimethoprim-sulphamethoxazole after renal transplantation. Hulme, B; Reeves, DS, 1971)	0.25
" A symptom complex of fevers and increasing malaise, often with nausea and headaches, developed usually after 9 days of therapy at a daily dosage of 20 mg/kg of trimethoprim and 100 mg/kg of sulphamethoxazole."	( Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Abrams, DI; Ammann, AJ; Golden, JA; Jaffe, HS; Lewis, BJ, 1983)	0.27
" The dosage of pivamdinocillin in adults was 400 to 800 mg, every 6 hours, for 10 to 16 days; dosage in children was half this amount for 11 to 15 days."	( Management of enteric fever with amdinocillin. Ball, AP; Geddes, AM, 1983)	0.27
"The purpose of this study was to identify new drugs for the prevention and treatment of Pneumocystis carinii pneumonitis (PCP) induced in rats by continuous daily dosage with dexamethasone."	( Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Hughes, WT; Smith, BL, 1984)	0.27
" The new sulfa-trimethoprim combination showed activity similar to the reference drug, but it may have the advantage of a simpler dosage schedule."	( Double-blind comparative trial of trimethoprim/sulfamethopyrazine once daily vs erythromycin 4 X daily in patients with ENT infections. Federspil, P; Koch, J, 1983)	0.27
" The same dosage was used in all cases: 2 mg/kg of TMP and 10 mg/kg of SMZ, given at bedtime."	( [Immunologic aspects of 2 modes of prevention of urinary tract infection in children with trimethoprim-sulfamethoxazole]. Labbé, J, 1984)	0.48
" When the creatinine clearance decreases to less than 30 ml/min, the dosage of trimethoprim-sulfamethoxazole should be adjusted."	( Trimethoprim-sulfamethoxazole. Cockerill, FR; Edson, RS, 1983)	0.86
" She recovered after surgical drainage of the abscesses and prolonged treatment with intravenous amikacin and high dosage cotrimoxazole and sulphadimidine."	( Abdominal nocardiosis in a Sudanese girl. Dickson, JA; Duerden, BI; Milner, RD; Salfield, SA, 1983)	0.27
" The dissolution rates were dependent on the pH of the dissolution medium, the solubilities of the drugs at the pH involved, the dosage form and the brand studied."	( Simultaneous in vitro and in vivo evaluation of both trimethoprim and sulfamethoxazole from certain dosage forms. El-Sabbagh, H; Foda, A; Ghanem, A; Meshali, M, 1983)	0.5
" Our data support the need for increased dosing or decreased dosing intervals when administering TMP-SMZ to patients with cystic fibrosis."	( Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. Bertino, JS; Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1984)	0.51
" The recommended dosage was trimethoprim, 150 mg/sq m/day, and sulfamethoxazole, 750 mg/sq m/day."	( Chemoprophylaxis for Pneumocystis carinii pneumonitis: outcome of unstructured delivery. Aur, RJ; Feldman, S; Hughes, WT; Malone, WJ; Ryan, M; Wilber, RB, 1980)	0.5
"2-82 years were treated intravenously with 150 mg of trimethoprim (TMP) and 750 mg of sulfamethoxazole (SMZ)/m2 every 8 hr, usually for known or suspected pneumocystis pneumonia; when necessary dosage was adjusted to maintain peak TMP levels of 5-10 micrograms/ml."	( Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Ericson, JF; Gorham, CC; Siber, GR; Smith, AL, )	0.61
" Thus, a regimen involving initial intravenous therapy with doses of 15-20 mg/kg per day, with subsequent reduction of dosage or change to oral medication if improvement is rapid, was developed."	( Trimethoprim-sulfamethoxazole in the treatment of adults with pneumonia due to Pneumocystis carinii. Young, LS, )	0.5
" Although the amount of SD was only about 1/3 of that of SM it seems to be a comparable alternative with this small dosage in combination with TMP, when bacterial infections in the urinary tract or in the male reproductive organs are treated."	( The penetration of sulfadiazine, sulfamethoxazole and trimethoprim into the prostate gland, epididymis and testis in man. Seppänen, J, 1980)	0.54
" Initial protocol dosing achieved target plasma levels of trimethoprim (3 to 8 micrograms/ml) or gentamicin (4 to 10 micrograms/ml) in 57 of 68 (84 per cent) C-T/S trials compared to 21 of 60 (35 per cent) C-G trials."	( Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. Braine, HG; Fuller, DJ; Lietman, PS; Saral, R; Stuart, RK, 1980)	0.56
" The initial dosage was given on an empty stomach, the second after a standard meal."	( [Relative clinical biological availability of a combination of trimethoprim-sulfamethoxazole in fasting children and after a meal]. Guggenbichler, JP; Takacs, F, 1980)	0.49
" Cefaclor in a twice daily dosage schedule appears to be a safe and useful drug in the treatment of urinary tract infections caused by the common gram-negative organisms and it appears to be as efficacious as the trimethoprim-sulfamethoxazole combination."	( A comparison of cefaclor versus trimethoprim-sulfamethoxazole combination in the treatment of acute urinary infections. Rous, SN, 1981)	0.71
"The traditional approach to the study of the interaction between antimicrobial agents relies on the assumption that inhibition of growth by antimicrobial agents follows a linear dose-response curve."	( The assessment of antimicrobial combinations. King, TC; Krogstad, DJ; Schlessinger, D, )	0.13
"Two dosage schedules of co-trimoxazole, the standard antibacterial and a 2-day high-dose schedule, were compared with a standard course of chloroquine in the treatment of uncomplicated Plasmodium falciparum malaria."	( An evaluation of co-trimoxazole in the treatment of Plasmodium falciparum malaria. Hansford, CF; Hoyland, J, 1982)	0.26
"Responses of parasitemia and fever in vivax malaria to standard doses of chloroquine and different dosage schedules of co-trimoxazole were compared in 165 children."	( A comparative trial of oral chloroquine and oral co-trimoxazole in vivax malaria in children. Lal, H, 1982)	0.26
" Dosage were made using HPLC after biological specimens had been treated on a TM C18 Set Pack column for deproteinization and isolation of the active substances."	( [Bone diffusion of trimethoprim and sulfamethoxazole high pressure liquid chromatography (HPLC) (author's transl)]. Le Rebeller, A; Leng, B; Mintrosse, J; Saux, MC, 1982)	0.54
" Nitrofurantoin macrocrystals were administered to 50 patients in a dosage of 100 mg every 12 hours for two days, trimethoprim/sulfamethoxazole was administered also to 50 patients in a dosage of 160 and 800 mg respectively every 12 hours for two days."	( [Short-term therapy of postoperative urinary tract infections in gynecology]. Hirsch, HA; Hoyme, UA; Niehues, U, 1982)	0.47
" The dosage schedule for TMP-SMX was 2 tablets every 12 h for nine doses, and for TMP-SMO it was 2 tablets as in the first dose, followed by 1 tablet every 12 h for eight more doses."	( Plasma levels of trimethoprim and sulfonamide after administration of trimethoprim-sulfamethoxazole and trimethoprim-sulfamoxole. Desai, NK; Gupta, KC; Paul, T; Sheth, UK, 1980)	0.49
"A rapid, sensitive, and automatable high-performance liquid chromatographic method is presented for the determination of sulfamethoxazole, trimethoprim, and a preservative in dosage forms in the presence of excipients and degradation products."	( High-performance liquid chromatographic analysis of trimethoprim and sulfamethoxazole in dosage forms. Sancilio, FD; Singletary, RO, 1980)	0.7
" cotrimoxazole (Sulprim, Polfa) was administered at a creatinine level to 3 mg/100 ml in a dosage of 3 times 1 tablet a day."	( [Therapy of urinary tract infection in kidney insufficiency with cotrimoxazole]. Jelińska, S; Kurkus, J; Siciński, A; Siemińska, J, 1980)	0.26
"Derivative and difference spectrophotometric methods are described for the direct simultaneous analysis of combinations of Trimethoprim with sulfonamide drugs (sulfadiazine, sulfamethoxazole, sulfamethoxypyridazine) in commercial dosage forms."	( Analysis of Trimethoprim--sulfonamide drug combinations in dosage forms by UV spectroscopy and liquid chromatography (HPLC). Andrisano, V; Bonazzi, D; Cavrini, V; Di Pietra, AM, 1994)	0.48
" Ro 11-8958, TMP, and diaveridine used at a dosage of 20 mg/kg/day with SMX were only slightly more effective than SMX used alone."	( Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Foy, J; Steele, P; Walzer, PD; White, M, 1993)	0.51
" Clinical trials are indicated to evaluate this dosing scheme, which may decrease exposure to potentially excessive concentrations of trimethoprim and sulfamethoxazole."	( Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Laizure, SC; Sanders, PL; Stein, DS; Stevens, RC, 1993)	0.71
" Thirty -six pigs were treated with trimethoprim/sulfatroxazole IM in the nec k at a dosage of 16 mg/kg body weight for five days."	( [Study of the elimination of residues and local tissue injury following intramuscular injection of a solution of the combination trimethoprim/sulfatroxazole in pigs]. Edwards, HJ; Kissmeyer, AM; Pott, JM; Skov, B; Szancer, J, 1996)	0.29
" In order to develop dosage schedules that would reliably achieve peak serum concentrations of TMP/SMX in the therapeutic range, we found that established dose leads to high fluctuations at steady state between C(max), ss and C(min), ss, without maintaining therapeutic levels."	( Kinetic effects of trimethoprim-sulfamethoxazole in children with biliary atresia: a new dosing regimen. Camacho, A; Lares-Asseff, I; López, DC; Pérez, G; Toledo, A; Villegas, F, 1996)	0.58
"0 mg/kg/day (10 rats per dosage and drug)."	( Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Hughes, WT; Killmar, J, 1996)	0.29
" bolus dosing were determined by reverse phase HPLC."	( The disposition of five therapeutically important antimicrobial agents in llamas. Christensen, JM; Hollingshead, N; Murdane, SB; Smith, BB, 1996)	0.29
" The immunogenic potential of SMX and its metabolites, SMX-NOH and SMX-NO, were assessed in rats by analyzing serum samples for the presence of anti-SMX IgG antibodies during a 4-week dosing period."	( The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. Gill, HJ; Hough, SJ; Kitteringham, NR; Maggs, JL; Naisbitt, DJ; Park, BK; Pirmohamed, M, 1997)	0.54
" The tremor resolved completely 3 days after a dosage reduction to TMP/SMX 15."	( Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS. Lerner, SA; Rybak, MJ; Slavik, RS, 1998)	0.67
" Using the lower end of the recommended dosing range for TMP/SMX (TMP 15 mg/kg/d) may reduce the incidence of these toxicities while still achieving acceptable TMP concentrations and antimicrobial efficacy."	( Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS. Lerner, SA; Rybak, MJ; Slavik, RS, 1998)	0.67
"5 or 30 micrograms/kg, depending on batch) and sulfamethoxazole (45 micrograms/kg) were established from dose-response curves."	( Delvotest SP for detection of cloxacillin and sulfamethoxazole in milk: IDF interlaboratory study. International Federation Dairy. Beukers, R; Suhren, G, )	0.65
" For a better understanding of the molecular basis of the recognition of such drugs by specific TCC, we investigated 1) the fine specificity of the recognizing TCR, 2) the dose-response relationship for the induction of proliferation or cytokine production, and 3) the mechanism of TCR triggering."	( Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. Burkhart, C; Frutig, K; Pichler, WJ; Schnyder, B; von Greyerz, S; Zanni, MP, 1999)	0.55
" In the chronic cystogenic murine models, the combination TMP plus SMX administered from day 5 for 15 days or from day 28 for 288 days, gave protection and even apparent toxoplasmal eradication ('cure') at the highest dosing (60/300 mg/kg per day)."	( Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Dumas, JL; Pechère, JC; Pizzolato, G, 1999)	0.3
"0 mg of sulphamethoxazole in pure and dosage forms."	( Indirect potentiometric titration of sulphamethoxazole in the presence of trimethoprim in co-trimazole tablets using copper based mercury film electrode. Abdul Kamal Nazer, M; Riyazuddin, P; Shabeer, TK, 2001)	0.31
" Male Wistar rats were dosed with sulphamethoxazole, sulphamethoxazole hydroxylamine or nitroso sulphamethoxazole."	( Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Burkhart, C; Cribb, AE; Gordon, SF; Naisbitt, DJ; Park, BK; Pichler, WJ; Pirmohamed, M, 2001)	0.31
" The treatment was effective, and the dosage of predonisolone had been gradually tapered."	( [A case of Nocardia farcinica pneumonia treated with sulfamethoxazole-trimethoprim monitoring its serum concentration]. Gotou, H; Igarashi, H; Kachi, S; Kawai, S; Kobayashi, H; Nakazato, Y; Ochi, M; Sekine, H; Takeda, H; Tashimo, Y; Watanabe, H, 2002)	0.56
" The method which is rapid, simple and does not require any separation step, has been successfully applied to the assay of commercial tablet and oral suspension dosage forms containing TMP and SPM."	( Simultaneous LC determination of trimethoprim and sulphamethoxazole in pharmaceutical formulations. Akay, C; Ozkan, SA, 2002)	0.31
" The dosage was: SMZco 400 mg/(kg."	( [PCR in evaluating the effect of allicin and its combination with SMZco on murine toxoplamosis]. Liu, PM; Shan, LY; Yang, XZ, 2003)	0.32
" In this study, the three spectrophotometric methods can be satisfactorily used for the quantitative analysis and for dissolution tests of multicomponent dosage forms."	( Chemometric and derivative methods as flexible spectrophotometric approaches for dissolution and assaying tests in multicomponent tablets. Koundourellis, JE; Malliou, ET; Markopoulou, CK, 2004)	0.32
" Dosing was by the intraperitoneal route, once daily for four consecutive days per week, for 2 weeks total, followed by a third week of observation."	( Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs: a pilot study. Lavergne, SN; Maki, JE; Trepanier, LA; Volkman, EM; Yoder, AR, 2005)	0.56
"Thirty-four privately owned sulphonamide HS dogs, 10 sulphonamide-'tolerant' dogs, 18 sulphonamide-naïve dogs, and four dogs experimentally dosed with SMX and the oxidative metabolite SMX-nitroso, were tested for drug-serum adducts by immunoblotting, and anti-drug antibodies by ELISA."	( Association of drug-serum protein adducts and anti-drug antibodies in dogs with sulphonamide hypersensitivity: a naturally occurring model of idiosyncratic drug toxicity. Danhof, RS; Lavergne, SN; Trepanier, LA; Volkman, EM, 2006)	0.33
" Anti-drug antibodies were also found in dogs experimentally dosed with SMX-nitroso followed by SMX, but not in a dog dosed with drug vehicle, followed by SMX."	( Association of drug-serum protein adducts and anti-drug antibodies in dogs with sulphonamide hypersensitivity: a naturally occurring model of idiosyncratic drug toxicity. Danhof, RS; Lavergne, SN; Trepanier, LA; Volkman, EM, 2006)	0.33
" The data suggested a tissue-specific threshold of SMX-NO dosage that triggers the detection of adducts and immune response."	( Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo. Cheng, L; Ju, C; Kawabata, TT; Petersen, DR; Piccotti, JR; Stewart, BJ; Ware, JA; You, Q, 2008)	0.6
" A pharmacokinetic (PK) simulation study was performed to determine the optimal dosing of cotrimoxazole (trimethoprim-sulfamethoxazole [TMP-SMX]) used in current eradication regimens in Thailand and Australia."	( Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. Amornchai, P; Cheng, AC; Chierakul, W; Day, NP; McBryde, ES; Peacock, SJ; White, NJ; Wuthiekanun, V, 2009)	0.82
" It was concluded that derivatization substantially changed the pharmaceutical properties, which have important role to play in formulation of solid dosage form."	( Comparative study of pharmaceutical properties of some new derivatives of sulfamethoxazole. Iqbal, MS; Khan, AH; Loother, BA, 2010)	0.59
"0 g/L) PAC dosage could be attributed to the fact that carbamazepine is relatively more hydrophobic than sulfamethoxazole, which subsequently resulted in its higher adsorption affinity toward PAC."	( Simultaneous activated carbon adsorption within a membrane bioreactor for an enhanced micropollutant removal. Hai, FI; Li, X; Nghiem, LD, 2011)	0.58
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" However, it is stated that a high ozone dosage would be necessary to achieve the complete mineralization of the intermediates."	( Bacterial community characterization of a sequencing batch reactor treating pre-ozonized sulfamethoxazole in water. Esplugas, M; González, O; Sans, C, )	0.35
" Adaptation of the biomass towards the dosed OMPs was not observed for a 6 month period, implying that new developed RBF sites might not be able to biodegrade compounds such as atrazine and sulfamethoxazole in the first few months of operation."	( Sorption and biodegradation of organic micropollutants during river bank filtration: a laboratory column study. Bertelkamp, C; Cabo, AJ; Cornelissen, ER; Reungoat, J; Reynisson, J; Singhal, N; van der Hoek, JP; Verliefde, AR, 2014)	0.59
" Increasing carbon dosage and contact time enhanced the removal of micropollutants."	( Adsorption characteristics of selected hydrophilic and hydrophobic micropollutants in water using activated carbon. Choi, DJ; Her, N; Kim, SK; Nam, SW; Zoh, KD, 2014)	0.4
" Testing of biological activity revealed limited potential for resistance to these agents, low toxicity, and highly effective in vivo activity, even with low dosing regimens."	( Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines. Burda, WN; Fleeman, R; Manetsch, R; Shaw, LN; Van Horn, KS, 2014)	0.4
" The experiments involved a fill and draw reactor, fed with acetate and continuous sulfamethoxazole dosing of 50 mg/L."	( Chronic impact of sulfamethoxazole on acetate utilization kinetics and population dynamics of fast growing microbial culture. Jonas, D; Kor-Bicakci, G; Orhon, D; Pala-Ozkok, I; Rehman, A; Ubay-Cokgor, E, 2014)	0.96
" Both DCF and SMX were removed from solution (adsorbed to GO), up to 35% and 12%, respectively, within 6h, and an increase in GO dosage enhanced the removal of DCF."	( Adsorption characteristics of diclofenac and sulfamethoxazole to graphene oxide in aqueous solution. Boateng, LK; Flora, JR; Her, N; Jung, C; Li, H; Nam, SW; Yoon, Y; Yu, M; Zoh, KD, 2015)	0.68
", HRT ∼ 125 min and catalyst dosage 529."	( Sulfamethoxazole in poultry wastewater: Identification, treatability and degradation pathway determination in a membrane-photocatalytic slurry reactor. Asha, RC; Kumar, M, 2015)	1.86
"This paper establishes a novel method to simultaneously predict the tablet weight (TW) and trimethoprim (TMP) content of compound sulfamethoxazole tablets (SMZCO) by near infrared (NIR) spectroscopy with partial least squares (PLS) regression for controlling the uniformity of dosage units (UODU)."	( High-throughput prediction of tablet weight and trimethoprim content of compound sulfamethoxazole tablets for controlling the uniformity of dosage units by NIR. Cao, L; Dong, Y; Fan, Q; Li, J; Luo, Y; Zhong, X, 2016)	0.87
" Fill and draw operation resumed with continuous sulfamethoxazole dosing of 50 mg/L and the chronic impact was evaluated with acclimated biomass after 20 days."	( Is the chronic impact of sulfamethoxazole different for slow growing culture? The effect of culture history. Jonas, D; Kor-Bicakci, G; Orhon, D; Pala-Ozkok, I; Ubay-Cokgor, E; Ural, A, 2016)	0.99
" The percentage of ƒT > MIC ranged between 43 and 100% of the dosing interval."	( Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016)	0.72
" The primary objective was to determine if weight-based dosing of these antibiotics is associated with better outcomes in cellulitis."	( Clinical outcomes in patients hospitalized with cellulitis treated with oral clindamycin and trimethoprim/sulfamethoxazole: The role of weight-based dosing. Alexander, B; Cox, KK; Heintz, BH; Livorsi, DJ, 2017)	0.67
"7%) received inadequate dosing of clindamycin (<10 mg/kg/day) or TMP/SMX (<5 mg TMP/kg per day) while 88 (42."	( Clinical outcomes in patients hospitalized with cellulitis treated with oral clindamycin and trimethoprim/sulfamethoxazole: The role of weight-based dosing. Alexander, B; Cox, KK; Heintz, BH; Livorsi, DJ, 2017)	0.67
"Inadequate dosing of clindamycin and TMP/SMX is independently associated with clinical failure in patients hospitalized with cellulitis."	( Clinical outcomes in patients hospitalized with cellulitis treated with oral clindamycin and trimethoprim/sulfamethoxazole: The role of weight-based dosing. Alexander, B; Cox, KK; Heintz, BH; Livorsi, DJ, 2017)	0.67
" The role of the catalyst under different UV wavelength, the role of permanganate in the treatment process, the effects of permanganate dosage and solution pH on the removal efficiency were investigated."	( Permanganate with a double-edge role in photodegradation of sulfamethoxazole: Kinetic, reaction mechanism and toxicity. Chu, W; Gong, H, 2018)	0.72
" A dose-response relationship of oxidative stress indicators including total-antioxidant capacity (T-AOC), inducible nitric oxide synthase (iNOS) and total nitric oxide synthase (TNOS), catalase (CAT) has been observed."	( Early exposure to environmental levels of sulfamethoxazole triggers immune and inflammatory response of healthy zebrafish larvae. Liu, J; Qiu, W; Wei, T; Wu, X; Zheng, Y; Zhong, H, 2020)	0.82
"Hormesis is an ecotoxicological phenomenon referred to as the biphasic dose-response effect."	( Elimination of the hormesis phenomenon by the use of synthetic sea water in a toxicity test towards Aliivibrio fischeri. Drzymała, J; Kalka, J, 2020)	0.56
" Intravenous sulfamethoxazole-trimethoprim (100 and 20 mg/kg/day) was administered in a dosing regimen every 6 hours."	( Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. Abdul-Aziz, MH; Dhanani, JA; Lipman, J; Livermore, A; Pandey, S; Pincus, J; Roberts, JA; Townsend, S; Wallis, SC, 2020)	1.25
" Organ pathological index also revealed that the intensity of tissue damage increased as sulfamethoxazole dosage was increased."	( Multi-biomarkers approach to determine the toxicological impacts of sulfamethoxazole antibiotic on freshwater fish Cyprinus carpio. Hashmi, I; Iftikhar, N; Zafar, R, 2022)	1.18
"Although there is a lack of data in trimethoprim-sulfamethoxazole (TMP-SMX) serum monitoring utility for invasive nocardial infections, therapeutic drug monitoring is widely used to optimize dosing and avoid adverse reactions that may cause treatment interruption."	( Observational study of the clinical utility of sulfamethoxazole serum level monitoring in the treatment of brain abscesses due to Nocardia species. Abu Saleh, O; Corsini Campioli, C; Mara, KC; Rivera, CG, 2022)	1.23
"Antibiotics are widely dosed in mariculture sector, resulting in substantial antibiotics residues."	( Sulfamethoxazole removal from mariculture wastewater in moving bed biofilm reactor and insight into the changes of antibiotic and resistance genes. Chen, Y; Gao, M; Guo, L; Ji, J; Maqbool, F; Wang, J; Zhang, M; Zhao, X; Zhao, YG, 2022)	2.16
" Two typical sulfonamides antibiotics (sulfamethoxazole, sulfadiazine) adsorption capacity were evaluated in terms of the dosage of composite materials, the ratio of each component, and the pH of the solution."	( Preparation of β-cyclodextrin/dopamine hydrochloride-graphene oxide and its adsorption properties for sulfonamide antibiotics. Deng, C; Ding, H; Liu, X; Xu, X; Yu, H; Yu, Z; Zhao, B; Zheng, K, 2022)	0.99
" Fixed bed column experiments with Al-modified biochar packed in different dosages (250, 500 and 1000 mg) and flow rates (1, 2 and 4 mL/min) showed the dosage of 1000 mg and flow rate of 1 mL/min performed the best for the removal of both SMX and SPY from wastewater."	( Fixed bed column performance of Al-modified biochar for the removal of sulfamethoxazole and sulfapyridine antibiotics from wastewater. Chen, H; Gao, B; Huang, J; Wan, Y; Yang, Y; Zhang, Y; Zheng, Y; Zimmerman, AR, 2022)	0.95
" Exposure to SMX at a sub-lethal dosage enhanced the prevalence of resistance genes sul1 and sul2 in resistant bacteria, thus implying high frequency of resistance dissemination in the marine environment and surrounding ecosystems."	( Sub-lethal concentration of sulfamethoxazole affects the growth performance of milkfish (Chanos chanos), the microbial composition of antibiotic-resistant bacteria and the prevalence of sulfonamide-resistance genes in mariculture. Chao, WL; Chen, YJ; Hsu, JT; Lau, SH; Li, ZF; Yeh, SL; Ying, C, 2022)	1.02
" Our results showed that MPs dosage affected the soil particles' SMX adsorption rate and capacity (Qe)."	( Do microplastics affect sulfamethoxazole sorption in soil? Experiments on polymers, ionic strength and fulvic acid. Cai, Y; Guo, T; Gustave, W; Li, B; Ouyang, D; Yu, B; Zhang, H; Zhao, T, 2023)	1.22
" The PEG-coated MNP showed higher stability in 10 consecutive reaction cycles, reduced leaching, and improved performance at a lower dosage and broader pH range than the uncoated MNPs."	( Heterogenous electro-Fenton degradation of sulfamethoxazole on a polyethylene glycol-coated magnetite nanoparticles catalyst. Arotiba, OA; Jayeola, KD; Muzenda, C; Nkwachukwu, OV; Zhou, M; Zinyemba, O, 2023)	1.17
" Furthermore, the influence of the following parameters of the vertical flow constructed wetlands on wastewater toxicity was investigated: the dosing system, the presence of pharmaceuticals and the plants Miscanthus giganteus."	( Effects of diclofenac, sulfamethoxazole, and wastewater from constructed wetlands on Eisenia fetida: impacts on mortality, fertility, and oxidative stress. Drzymała, J; Kalka, J, 2023)	1.22

Role	Description
antibacterial agent	A substance (or active part thereof) that kills or slows the growth of bacteria.
antiinfective agent	A substance used in the prophylaxis or therapy of infectious diseases.
epitope	The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
EC 2.5.1.15 (dihydropteroate synthase) inhibitor	An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
P450 inhibitor	An enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor	An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the activity of sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming), EC 1.1.1.153, which plays an important part in the biosynthesis of tetrahydrobiopterin.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
drug allergen	Any drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
isoxazoles	Oxazoles in which the N and O atoms are adjacent.
substituted aniline
sulfonamide antibiotic	A class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
interleukin 8	Homo sapiens (human)	Potency	66.8242	0.0473	49.4806	74.9780	AID651758
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.6682	0.0007	14.5928	83.7951	AID1259369
Microtubule-associated protein tau	Homo sapiens (human)	Potency	8.9125	0.1800	13.5574	39.8107	AID1468
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	11.2202	0.0112	12.4002	100.0000	AID1030
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	29.8493	0.0015	30.6073	15,848.9004	AID1224841
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	54.4372	0.3758	27.4851	61.6524	AID743217
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	30.2788	0.0002	29.3054	16,493.5996	AID588513; AID743069; AID743079
activating transcription factor 6	Homo sapiens (human)	Potency	11.9856	0.1434	27.6121	59.8106	AID1159516
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	13.3332	0.0003	23.4451	159.6830	AID743065
ubiquitin carboxyl-terminal hydrolase 2 isoform a	Homo sapiens (human)	Potency	43.2397	0.6561	9.4520	25.1189	AID652173
geminin	Homo sapiens (human)	Potency	25.9290	0.0046	11.3741	33.4983	AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
exodeoxyribonuclease V subunit RecB	Escherichia coli str. K-12 substr. MG1655	IC50 (µMol)	106.4380	0.1000	0.1000	0.1000	AID492957; AID652151
exodeoxyribonuclease V subunit RecC	Escherichia coli str. K-12 substr. MG1655	IC50 (µMol)	106.4380	0.1000	0.1000	0.1000	AID492957; AID652151
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
ATP-dependent 6-phosphofructokinase	Trypanosoma brucei brucei	IC50 (µMol)	57.0000	3.0000	3.0000	3.0000	AID1064827
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	422.6667	0.1100	7.1903	10.0000	AID1443980; AID1449628; AID1473738
Dihydropteroate synthase	Escherichia coli K-12	IC50 (µMol)	4.7000	2.5000	3.6000	4.7000	AID55870
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	4.7000	0.0004	0.9086	10.0000	AID55870
Dihydrofolate reductase	Pneumocystis carinii	IC50 (µMol)	0.1000	0.0006	0.5476	6.2000	AID55837
Endothelin-1 receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	223.3333	0.0000	1.7746	10.0000	AID1626376; AID66057; AID66184
Protease	Human immunodeficiency virus 1	Ki	0.0101	0.0000	0.0443	3.1000	AID238682
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Protein-arginine deiminase type-4	Homo sapiens (human)	IC50 (µMol)	10,000.0000	2.5000	4.2000	5.9000	AID320706
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Protease	Human immunodeficiency virus 1	Kd	0.5770	0.0001	0.0412	0.5770	AID238043
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to xenobiotic stimulus	Dihydropteroate synthase	Escherichia coli K-12
folic acid biosynthetic process	Dihydropteroate synthase	Escherichia coli K-12
folic acid-containing compound biosynthetic process	Dihydropteroate synthase	Escherichia coli K-12
tetrahydrofolate biosynthetic process	Dihydropteroate synthase	Escherichia coli K-12
folic acid biosynthetic process	Dihydropteroate synthase	Escherichia coli K-12
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
chromatin organization	Protein-arginine deiminase type-4	Homo sapiens (human)
nucleosome assembly	Protein-arginine deiminase type-4	Homo sapiens (human)
chromatin remodeling	Protein-arginine deiminase type-4	Homo sapiens (human)
stem cell population maintenance	Protein-arginine deiminase type-4	Homo sapiens (human)
protein modification process	Protein-arginine deiminase type-4	Homo sapiens (human)
post-translational protein modification	Protein-arginine deiminase type-4	Homo sapiens (human)
innate immune response	Protein-arginine deiminase type-4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
dihydropteroate synthase activity	Dihydropteroate synthase	Escherichia coli K-12
transferase activity	Dihydropteroate synthase	Escherichia coli K-12
metal ion binding	Dihydropteroate synthase	Escherichia coli K-12
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein-arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
calcium ion binding	Protein-arginine deiminase type-4	Homo sapiens (human)
protein binding	Protein-arginine deiminase type-4	Homo sapiens (human)
identical protein binding	Protein-arginine deiminase type-4	Homo sapiens (human)
histone arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R2 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R8 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R17 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
histone H3R26 arginine deiminase activity	Protein-arginine deiminase type-4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytoplasm	Dihydropteroate synthase	Escherichia coli K-12
cytosol	Dihydropteroate synthase	Escherichia coli K-12
cytosol	Dihydropteroate synthase	Escherichia coli K-12
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
nucleus	Protein-arginine deiminase type-4	Homo sapiens (human)
nucleoplasm	Protein-arginine deiminase type-4	Homo sapiens (human)
cytosol	Protein-arginine deiminase type-4	Homo sapiens (human)
protein-containing complex	Protein-arginine deiminase type-4	Homo sapiens (human)
nucleus	Protein-arginine deiminase type-4	Homo sapiens (human)
cytoplasm	Protein-arginine deiminase type-4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID557799	Antimicrobial activity against Escherichia coli J53 by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
AID374113	Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID440775	Antibacterial activity against Salmonella Typhimurium ATTC 23564 at 1 mg/ml after 24 hrs by well-diffusion method	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis and antibacterial activity of some novel bis-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and bis-4-thiazolidinone derivatives from terephthalic dihydrazide.
AID197602	Lysozyme-conjugated prodrugs: in vitro stability in rat cortical homogenate at pH 7.4	1992	Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID26320	pKa value is evaluated	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID542759	Antimicrobial activity against Escherichia coli Du19 expressing qnrB6 and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID1496669	Antibacterial activity against Staphylococcus aureus NCIM 2079 after 24 hrs by broth micro dilution method
AID425612	Cytotoxicity against mouse J774A1 cells assessed as release of adenylate kinase at 100 ug/ml after 3 hrs by total cell protein assay relative to control	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID1314009	Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 measured after 18 hrs by broth dilution method	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID1404665	Synergistic antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in presence of TMP after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID542769	Antimicrobial activity against Escherichia coli J53 transformed with pHND1 carrying DHA-1 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID440774	Antibacterial activity against Bacillus cereus ATTC 10702 at 1 mg/ml after 24 hrs by well-diffusion method	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis and antibacterial activity of some novel bis-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and bis-4-thiazolidinone derivatives from terephthalic dihydrazide.
AID66699	Binding affinity towards displacement of [125 I] ET-3 from COS-7 cells transfected with porcine Endothelin B receptor.	2000	Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16	Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
AID495748	Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID649899	Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID542771	Antimicrobial activity against Escherichia coli J53 transformed with pHND3 carrying qnrB6 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID649913	Antibacterial activity against Pseudomonas aeruginosa CCM 1961 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID70301	Antibacterial activity against Escherichia coli at a concentration of 10 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID650055	Selectivity ratio of IC50 for human HepG2 cell sto MIC90 for Staphylococcus aureus CCM 4516/08	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID251950	Zone of inhibition of Pseudomonas aeruginosa at compound concentration of 40 mg/mL; ND denotes ''not determined''	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1404678	Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in presence of TMP-I after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1890859	Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1889627	Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1278495	Antibacterial activity against Proteus sp. at 100 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1854158	Antimicrobial activity against Enterobacter cloacae incubated for 18 to 24 hrs	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID425602	Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate LF82 in mouse J774A1 cells isolated from chronic ileal lesions of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax after	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID561103	Antibacterial activity against Pasteurella multocida BB1037 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1851931	Plasma protein binding in human	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID542766	Antimicrobial activity against Escherichia coli PA11 expressing aac(6')-Ib-cr, qnrS1 and qepA genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID289692	Antibacterial activity against Pasteurella multocida at 20 mg/ml by paper disc method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID750773	Antimicrobial activity against Escherichia coli ATCC 35218 after 24 hrs by broth micro serial dilution method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1314011	Drug level assessed as Staphylococcus saprophyticus ATCC 15305 nitroreductase B mediated compound formation using 130 uM NO2-SMX measured after 200 mins in presence of NADPH-cofactor generating system by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID1889626	Antibacterial activity against Escherichia coli 25922 assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID238682	Inhibition constant for human immunodeficiency virus type 1 protease	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID1314006	Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 assessed as zone of inhibition at 51 ug/disc measured after 16 to 24 hrs by agar diffusion method	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID1854159	Antimicrobial activity against Staphylococcus aureus incubated for 18 to 24 hrs	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID289689	Antibacterial activity against Salmonella enteritidis at 20 mg/ml by paper disc method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID1278493	Antibacterial activity against Escherichia coli at 100 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID750780	Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID524593	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID425400	Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID561105	Antibacterial activity against Pasteurella multocida BB1039 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID750784	Antimicrobial activity against Salmonella typhi ATCC 23564 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID251665	Zone of inhibition of Escherichia coli at compound concentration of 40 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID562810	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID561101	Antibacterial activity against Pasteurella multocida BB1035 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID242866	Dissociation rate constant for human immunodeficiency virus type 1 protease	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID577199	Increase in shiga toxin production in Escherichia coli C600::933W encoding Stx-2 gene at 0.5 X MIC by luciferase assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID253055	Antibacterial activity of compound against Escherichia coli at 80 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID750776	Antimicrobial activity against Escherichia coli ATCC 35218 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID649904	Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1854160	Antimicrobial activity against Pseudomonas aeruginosa incubated for 18 to 24 hrs	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID253057	Antibacterial activity of compound against Bacillus subtilis at 20 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID1404688	Synergistic antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL in presence of TMP-Br after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID535651	Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1278496	Antibacterial activity against Staphylococcus aureus at 100 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID532190	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1404662	Potentiation of TMP-Br-mediated antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 assessed as TMP-Br MIC after 20 hrs by CLSI microdilution assay (Rvb = 1.25 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1653055	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by agar well diffusion technique	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Isatin derivatives and their anti-bacterial activities.
AID1890853	Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID649911	Antibacterial activity against Klebsiella pneumoniae D 11750/08 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID532187	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26T harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID373983	Antimicrobial activity Escherichia coli 633 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID1141112	Antimicrobial activity against Serratia marcescens ATCC 14576 at 128 uM after 24 to 48 hrs by two-fold broth microdilution method	2014	Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10	Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.
AID561104	Antibacterial activity against Pasteurella multocida BB1038 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID251672	Zone of inhibition of Bacillus subtilis at compound concentration of 80 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID253065	Antibacterial activity of compound against Klebsiella pneumoniae at 40 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID577202	Increase in shiga toxin production in Escherichia coli O157:H7 PT-32 encoding Stx-1 and Stx-2 gene at subinhibitory concentration by luciferase assay relative to untreated control	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID495753	Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime-cluvulanic acid by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID535900	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID320706	Inhibition of PAD4 by ABPP-based assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
AID670244	Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microbroth dilution method	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	Synthesis and antimycobacterial activity of some phthalimide derivatives.
AID561110	Antibacterial activity against Pasteurella multocida BB1044 harboring plasmid pB1000 bearing blaROB-1 gene, plasmid 1006 bearing tetO gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID535657	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1278489	Antibacterial activity against Escherichia coli at 50 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID425601	Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax a	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID251681	Zone of inhibition of Salmonella typhae at compound concentration of 160 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID94079	Antibacterial activity against Klebsiella pneumoniae at a concentration of 120 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID577205	Antimicrobial activity against Escherichia coli O157:H7 PT-32 in logarithmic phase encoding Stx-1 and Stx-2 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID94205	Antibacterial activity against Klebsiella pneumoniae at a concentration of 80 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID535654	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ61 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID197730	Lysozyme-conjugated prodrugs: in vitro stability in buffered plasma at pH 7.4	1992	Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID1404683	Potentiation of TMP-Br-mediated antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL assessed as TMP-Br MIC after 20 hrs by CLSI microdilution assay (Rvb = 5 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID532172	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1890861	Antibacterial activity against Acinetobacter baumannii assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID577208	Antimicrobial activity against Escherichia coli C600::H19B in logarithmic phase encoding Stx-1 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID530347	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID649909	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 48 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1404686	Synergistic antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL in presence of TMP after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID542737	Antimicrobial activity against Klebsiella pneumoniae D24 expressing aac(6')-Ib-cr and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1854157	Antimicrobial activity against Enterococcus faecium incubated for 18 to 24 hrs	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID1278488	Antibacterial activity against Staphylococcus aureus at 10 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID535666	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67 harboring wild-type GyrA S83I and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID251667	Zone of inhibition of Escherichia coli at compound concentration of 160 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID577206	Antimicrobial activity against Escherichia coli O157:H7 PT-32 in stationary phase encoding Stx-1 and Stx-2 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID535660	Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63 harboring GyrA S83I, GyrA D87A, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1890856	Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID649902	Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1188962	Aqueous solubility of the compound in H2O after 24 hrs incubation at 30 degC by LCMS analysis	2014	ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8	An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility.
AID532175	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae SH39T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID497729	Inhibition of IPTG-stimulated Escherichia coli K-12 tolC at 8 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID70305	Antibacterial activity against Escherichia coli at a concentration of 40 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID408619	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by conventional agar dilution method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis, in vitro antibacterial and carbonic anhydrase II inhibitory activities of N-acylsulfonamides using silica sulfuric acid as an efficient catalyst under both solvent-free and heterogeneous conditions.
AID541856	Antimicrobial activity against florfenicol-resistant Edwardsiella ictaluri M07-1 by microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID440773	Antibacterial activity against Klebsiella pneumoniae ATCC 10031 at 1 mg/ml after 24 hrs by well-diffusion method	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis and antibacterial activity of some novel bis-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and bis-4-thiazolidinone derivatives from terephthalic dihydrazide.
AID535663	Antimicrobial activity against aac(6')-Ib-cr-positive Enterobacter cloacae FJ63T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1496670	Antibacterial activity against wild type Escherichia coli NCIM 2065 after 24 hrs by broth micro dilution method
AID251697	Zone of inhibition of Klebsiella pneumoniae at compound concentration of 40 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1404660	Potentiation of TMP-mediated antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 assessed as TMP MIC after 20 hrs by CLSI microdilution assay (Rvb = 1.25 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1889620	Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1404681	Potentiation of TMP-mediated antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL assessed as TMP MIC after 20 hrs by CLSI microdilution assay (Rvb = 5 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID13311	Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID562811	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID497888	Inhibition of IPTG-stimulated Escherichia coli K-12 rpSR at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID373982	Antimicrobial activity Enterobacter cloacae 641 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID1653053	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by agar well diffusion technique	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Isatin derivatives and their anti-bacterial activities.
AID650051	Antifungal activity against Aspergillus fumigatus 231 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID408614	Antibacterial activity against Escherichia coli isolate by conventional agar dilution method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis, in vitro antibacterial and carbonic anhydrase II inhibitory activities of N-acylsulfonamides using silica sulfuric acid as an efficient catalyst under both solvent-free and heterogeneous conditions.
AID562812	Antimicrobial activity against Escherichia coli DH5[alpha]	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID649912	Antibacterial activity against ESBL-positive Klebsiella pneumoniae J 14368/08 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID64418	Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.4	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID750777	Antimicrobial activity against Pseudomonas aeruginosa ATCC 15499 after 24 hrs by broth micro serial dilution method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1890860	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID239819	Association rate constant for human immunodeficiency virus type 1 protease	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1889624	Antibacterial activity against Klebsiella pneumoniae assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID253054	Antibacterial activity of compound against Escherichia coli at 40 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID197728	Lysozyme-conjugated prodrugs: in vitro stability in lysosomal lysate at pH 7.4	1992	Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID1217705	Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1404668	Synergistic antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in presence of TMP-I after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1278491	Antibacterial activity against Proteus sp. at 50 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1278494	Antibacterial activity against Pseudomonas aeruginosa at 100 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID425604	Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM615 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax a	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID497885	Inhibition of IPTG-stimulated Escherichia coli K-12 tolC at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1404691	Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in presence of TMP-Br after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1217706	Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID535894	Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID495752	Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID532205	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID251706	Zone of inhibition of Staphylococcus aureus at compound concentration of 160 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1889628	Antibacterial activity against Pseudomonas aeruginosa 27853 assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID542768	Antimicrobial activity against Escherichia coli J53 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1278490	Antibacterial activity against Pseudomonas aeruginosa at 50 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID535885	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID535873	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1404654	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL after 20 hrs by CLSI microdilution assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID408616	Antibacterial activity against Klebsiella pneumoniae isolate by conventional agar dilution method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis, in vitro antibacterial and carbonic anhydrase II inhibitory activities of N-acylsulfonamides using silica sulfuric acid as an efficient catalyst under both solvent-free and heterogeneous conditions.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID532208	Antimicrobial activity against Escherichia coli J53 harboring wild-type GyrA, ParC, GyrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID649893	Selectivity ratio of IC50 for human HepG2 cell sto MIC100 for Mycobacterium kansasii 235/80	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1890855	Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID532178	Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID532181	Antimicrobial activity against aac(6')-Ib-cr-negative Klebsiella pneumoniae SY22T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID40933	Antibacterial activity against Bacillus subtilis at a concentration of 80 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID374136	Antimicrobial activity Enterobacter cloacae 91 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID530349	Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID1534183	Antimicrobial activity against autoluminescent Mycobacterium tuberculosis H37Ra assessed as test compound concentration causing ratio of drug treated RLU/untreated RLU less than 10% measured every day up to 6 days by luminometric method	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents.
AID649897	Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 21 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1404652	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 after 20 hrs by CLSI microdilution assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID535864	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID253059	Antibacterial activity of compound against Bacillus subtilis at 80 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID535648	Antimicrobial activity against aac(6')-Ib-cr-positive Escherichia coli FJ3 harboring GyrA S83L, ParC S80R mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID55870	In vitro inhibition of dihydropteroate synthase from Escherichia coli.	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	Monocyclic pteridine analogues. Inhibition of Escherichia coli dihydropteroate synthase by 6-amino-5-nitrosoisocytosines.
AID289690	Antibacterial activity against Salmonella enteritidis at 30 mg/ml by paper disc method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID1404689	Synergistic antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL in presence of TMP-I after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1314010	Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 assessed as bacterial survival measured after 18 hrs by broth dilution method	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID541855	Antimicrobial activity against Escherichia coli ATCC 29522 by microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID542770	Antimicrobial activity against Escherichia coli J53 transformed with pHND2 carrying qnrB6 and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID1889623	Antibacterial activity against Staphylococcus aureus 29213 assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID530348	Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID425582	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by Etest antibiotic concentration gradient method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID1404671	Potentiation of TMP-mediated antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as TMP MIC after 20 hrs by CLSI microdilution assay (Rvb = 1.25 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID66057	Antagonism of [125 I]ET-1 binding to the rat endothelin receptor in vascular smooth muscle VSM-A10 cells.	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
AID577209	Antimicrobial activity against Escherichia coli C600::933W in logarithmic phase encoding Stx-2 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID650056	Selectivity ratio of IC50 for human HepG2 cell sto MIC90 for methicillin-resistant Staphylococcus aureus H 5996/08	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID440772	Antibacterial activity against Escherichia coli ATTC 25922 at 1 mg/ml after 24 hrs by well-diffusion method	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis and antibacterial activity of some novel bis-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and bis-4-thiazolidinone derivatives from terephthalic dihydrazide.
AID535882	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID374137	Antimicrobial activity Enterobacter cloacae 113 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID577201	Increase in shiga toxin production in Escherichia coli O157:H7 PT-40 encoding Stx-2 gene at 0.5 X MIC by luciferase assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID542773	Antimicrobial activity against Escherichia coli J53 transformed with pHNPA1 carrying qnrB6 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID650058	Antimycobacterial activity against Mycobacterium avium complex	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID497886	Inhibition of IPTG-stimulated Escherichia coli K-12 yjeE at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID532196	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42 harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1505184	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by lactate dehydrogenase assay	2018	Journal of natural products, 01-26, Volume: 81, Issue:1	Synthesis and Bioactivity of Reduced Chalcones Containing Sulfonamide Side Chains.
AID497731	Inhibition of IPTG-stimulated Escherichia coli K-12 rpSR at 8 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID497736	Inhibition of IPTG-stimulated Escherichia coli K-12 folC at 8 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID541857	Antimicrobial activity against Escherichia coli ATCC 29522 carrying Edwardsiella ictaluri pM07-1 by microdilution assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.
AID197726	Lysozyme-conjugated prodrugs: in vitro stability in lysosomal lysate at pH 5	1992	Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID649894	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649892	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1404684	Potentiation of TMP-I-mediated antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL assessed as TMP-I MIC after 20 hrs by CLSI microdilution assay (Rvb = 2.50 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID535876	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JN1T by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID251962	Zone of inhibition of Pseudomonas aeruginosa at compound concentration of 160 mg/mL; ND denotes ''not determined''	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1404674	Potentiation of TMP-I-mediated antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as TMP-I MIC after 20 hrs by CLSI microdilution assay (Rvb = 1.25 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1404663	Potentiation of TMP-I-mediated antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 assessed as TMP-I MIC after 20 hrs by CLSI microdilution assay (Rvb = 1.25 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID561102	Antibacterial activity against Pasteurella multocida BB1036 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1005 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1496672	Antibacterial activity against Escherichia coli U-621 mutant after 24 hrs by broth micro dilution method
AID1496668	Antibacterial activity against Bacillus cereus NCIM 2156 after 24 hrs by broth micro dilution method
AID373984	Antimicrobial activity Escherichia coli 650 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID535861	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ47 harboring qnrB and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1653056	Antibacterial activity against Shigella dysenteriae after 24 hrs by agar well diffusion technique	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Isatin derivatives and their anti-bacterial activities.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID562813	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID542735	Antimicrobial activity against Klebsiella pneumoniae D10 expressing aac(6')-Ib-cr, qnrB4, CTX-M-1G and DHA-1 genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID1404682	Potentiation of TMP-Cl-mediated antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL assessed as TMP-Cl MIC after 20 hrs by CLSI microdilution assay (Rvb = 5 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID561099	Antibacterial activity against Pasteurella multocida ATCC 43137 by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID197600	Lysozyme-conjugated prodrugs: in vitro stability in rat cortical homogenate at pH 5	1992	Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID1404653	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 after 20 hrs by CLSI microdilution assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1404672	Potentiation of TMP-Cl-mediated antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as TMP-Cl MIC after 20 hrs by CLSI microdilution assay (Rvb = 2.50 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID251674	Zone of inhibition of Salmonella typhae at compound concentration of 40 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID283150	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5204 isolate from prosthetic joint infection patient by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID562809	Antimicrobial activity against Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID253064	Antibacterial activity of compound against Klebsiella pneumoniae at 20 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID253056	Antibacterial activity of compound against Bacillus subtilis at 10 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID532166	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55 harboring GyrA T83I, ParC S80I mutant, wild-type GyrB, qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID530346	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID535867	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51 harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID197598	Lysozyme-conjugated prodrugs: in vitro stability at pH 7.4	1992	Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID66184	Displacement of [125 I] ET-1 from rat aortic smooth muscle A7r5 cells transfected with Endothelin A receptor	2000	Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16	Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
AID577207	Antimicrobial activity against Escherichia coli C600::H19B in stationary phase encoding Stx-1 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID1890854	Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1064827	Inhibition of Trypanosoma brucei PFK-mediated ADP production using ATP/fructose-6-phosphate as substrate by luciferase based luminescence assay	2014	ACS medicinal chemistry letters, Jan-09, Volume: 5, Issue:1	Identification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase.
AID649905	Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 48 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID289691	Antibacterial activity against Salmonella enteritidis at 40 mg/ml by paper disc method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID1653054	Antibacterial activity against Bacillus cereus after 24 hrs by agar well diffusion technique	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Isatin derivatives and their anti-bacterial activities.
AID374111	Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS5 transconjugant from Enterobacter cloacae 641 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID1899208	Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	The discovery of 1, 3-diamino-7H-pyrrol[3, 2-f]quinazoline compounds as potent antimicrobial antifolates.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID650054	Selectivity ratio of IC50 for human HepG2 cell sto MIC100 for Mycobacterium kansasii 6509/96	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID342022	Antibacterial activity against plasmid pK29 transconjugant Escherichia coli J53 by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID251666	Zone of inhibition of Escherichia coli at compound concentration of 80 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID561100	Antibacterial activity against Pasteurella multocida BB1034 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB1001 bearing tetB gene by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1138716	Antimicrobial activity against wild type Staphylococcus aureus	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines.
AID1889625	Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID495750	Antimicrobial activity against Escherichia coli J5 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID542772	Antimicrobial activity against Escherichia coli J53 transformed with pHNDU1 carrying qnrB6 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID535903	Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12 harboring GyrA S83L mutant, wild-type GyrB, ParC and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID535858	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID649903	Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649900	Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID342021	Antibacterial activity against Klebsiella pneumoniae NK29 by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID495749	Antimicrobial activity against Salmonella enterica serotype Virchow 3464b by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID139106	Effect on Candida albicans nephritis and Meningitis in Immunosuppressed Mice brain	1996	Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4	High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID280386	Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation	2007	Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6	Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
AID253052	Antibacterial activity of compound against Escherichia coli at 10 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID253058	Antibacterial activity of compound against Bacillus subtilis at 40 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID535888	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN41T harboring qnrB gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID251700	Zone of inhibition of Staphylococcus aureus at compound concentration of 80 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1278492	Antibacterial activity against Staphylococcus aureus at 50 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1889619	Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID374135	Antimicrobial activity Enterobacter cloacae 63 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID1890852	Antibacterial activity against Klebsiella pneumoniae assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1585791	Protein binding in human plasma at 5 uM after 30 mins by LC-MS/MS analysis based ultrafiltration method	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.
AID535870	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae GZ51T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID40931	Antibacterial activity against Bacillus subtilis at a concentration of 40 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID409958	Inhibition of bovine brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID251679	Zone of inhibition of Bacillus subtilis at compound concentration of 160 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID425609	Cytotoxicity against mouse J774A1 cells assessed as macrophage number at 40 to 60 ug/ml after 3 hrs by total cell protein assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID24211	Compound is evaluated for ionization constant log k	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID625276	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID625294	Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID40929	Antibacterial activity against Bacillus subtilis at a concentration of 160 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID238043	Binding affinity for human immunodeficiency virus type 1 protease	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID1890857	Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1404687	Synergistic antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL in presence of TMP-Cl after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID649896	Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 14 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1626376	Displacement of 125I-ET1 from ETA receptor in rat A7R5 cells	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
AID425583	Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID599144	Intrinsic solubility, log 1/S0 of the compound	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID94081	Antibacterial activity against Klebsiella pneumoniae at a concentration of 160 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1141104	Antimicrobial activity against Escherichia coli ATCC 25922 after 24 to 48 hrs by two-fold broth microdilution method	2014	Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10	Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.
AID408615	Antibacterial activity against Enterococcus faecium isolate by conventional agar dilution method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis, in vitro antibacterial and carbonic anhydrase II inhibitory activities of N-acylsulfonamides using silica sulfuric acid as an efficient catalyst under both solvent-free and heterogeneous conditions.
AID1278487	Antibacterial activity against Proteus sp. at 10 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID750785	Antimicrobial activity against Bacillus cereus MTCC 7350 after 24 hrs by broth micro serial dilution method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID530350	Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID1314008	Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 measured after 18 hrs by agar dilution method	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID649907	Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 48 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID535855	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae GZ40 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID649910	Antibacterial activity against Escherichia coli CCM 4517 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID425392	Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease in mouse J774A1 cells assessed as intracellular killing of bacteria at 40 to 60 ug/ml afte	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID495751	Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID535879	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae JN132 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID70303	Antibacterial activity against Escherichia coli at a concentration of 20 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID561111	Antibacterial activity against Pasteurella multocida BB1045 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID253063	Antibacterial activity of compound against Klebsiella pneumoniae at 10 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID40927	Antibacterial activity against Bacillus subtilis at a concentration of 120 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID246965	Effective dose of compound required to inhibit replication of human immunodeficiency virus type 1 in MT-4 cells	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID1404661	Potentiation of TMP-Cl-mediated antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 assessed as TMP-Cl MIC after 20 hrs by CLSI microdilution assay (Rvb = 1.25 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID577210	Antimicrobial activity against Escherichia coli C600::933W in stationary phase encoding Stx-2 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID532163	Antimicrobial activity against aac(6')-Ib-cr-negative Escherichia coli PU12T harboring wild-type GyrA, GyrB, ParC and qnrS genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1278486	Antibacterial activity against Pseudomonas aeruginosa at 10 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID577200	Increase in shiga toxin production in Escherichia coli O157:H7 PT-32 encoding Stx-1 and Stx-2 gene at 0.5 X MIC by luciferase assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID1404676	Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in presence of TMP after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID425603	Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM580 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax a	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID408617	Antibacterial activity against Staphylococcus aureus isolate by conventional agar dilution method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis, in vitro antibacterial and carbonic anhydrase II inhibitory activities of N-acylsulfonamides using silica sulfuric acid as an efficient catalyst under both solvent-free and heterogeneous conditions.
AID557797	Antimicrobial activity against Escherichia coli J53 transconjugated with Proteus mirabilis pHS10 carrying qnrC gene by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
AID66201	Inhibition of [125I]endothelin-l binding to endothelin A receptor of rat thoracic aorta smooth muscle cells	1995	Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4	Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors.
AID625293	Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID253066	Antibacterial activity of compound against Klebsiella pneumoniae at 80 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID561112	Antibacterial activity against Pasteurella multocida BB1046 harboring plasmid pB1003 bearing blaROB-1 gene and plasmid pB1002 bearing strA, sul2 genes by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID251675	Zone of inhibition of Salmonella typhae at compound concentration of 80 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1851932	Plasma protein binding in mouse	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID251951	Zone of inhibition of Pseudomonas aeruginosa at compound concentration of 80 mg/mL; ND denotes ''not determined''	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID577198	Increase in shiga toxin production in Escherichia coli C600::H19B encoding Stx-1 gene at 0.5 X MIC by luciferase assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID251699	Zone of inhibition of Staphylococcus aureus at compound concentration of 40 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID342023	Antibacterial activity against Escherichia coli J53 by broth microdilution test	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID561109	Antibacterial activity against Pasteurella multocida BB1043 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID532199	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae WH42T harboring qnrA gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID649908	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID373986	Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS3 transconjugant from Citrobacter freundii 64 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID750789	Antimicrobial activity against Staphylococcus aureus ATCC 11632 after 24 hrs by broth micro serial dilution method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1899221	Antibacterial activity against ESBL-producing Klebsiella pneumoniae CCPM(A)-081514 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	The discovery of 1, 3-diamino-7H-pyrrol[3, 2-f]quinazoline compounds as potent antimicrobial antifolates.
AID1889621	Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID649906	Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 24 hrs by broth microdilution method	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID167576	In vitro functional antagonistic testing by obtaining ET-1 concentration response curves in rabbit carotid artery rings in the presence or absence of antagonist.	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
AID253053	Antibacterial activity of compound against Escherichia coli at 20 ug/mL expressed as zone of inhibition	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID750792	Antimicrobial activity against Staphylococcus aureus ATCC 11632 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID1404673	Potentiation of TMP-Br-mediated antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as TMP-Br MIC after 20 hrs by CLSI microdilution assay (Rvb = 1.25 microg/ml)	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID532169	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii PU55T harboring wild-type GyrA, ParC, GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID373985	Antimicrobial activity Citrobacter freundii 64 expressing plasmid-mediated quinolone resistance qnr A gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID750788	Antimicrobial activity against Bacillus cereus MTCC 7350 assessed as diameter of inhibition zone at 80 uM after 24 hrs by Kirby -Baur disc diffusion method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID649901	Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1404667	Synergistic antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in presence of TMP-Br after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID55837	Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii in the prence of 100 micro M PABA.	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID373987	Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS4 transconjugant from Enterobacter cloacae 91 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID561108	Antibacterial activity against Pasteurella multocida BB1042 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID408618	Antibacterial activity against Staphylococcus aureus ATCC 25922 by conventional agar dilution method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis, in vitro antibacterial and carbonic anhydrase II inhibitory activities of N-acylsulfonamides using silica sulfuric acid as an efficient catalyst under both solvent-free and heterogeneous conditions.
AID374112	Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS6 transconjugant from Escherichia coli 650 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID577203	Antimicrobial activity against Escherichia coli O157:H7 PT-40 in logarithmic phase encoding Stx-2 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID535852	Antimicrobial activity against aac(6')-Ib-cr-negative Enterobacter cloacae FJ67T harboring qnrS gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID251703	Zone of inhibition of Klebsiella pneumoniae at compound concentration of 160 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID750781	Antimicrobial activity against Salmonella typhi ATCC 23564 after 24 hrs by broth micro serial dilution method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
AID197596	Lysozyme-conjugated prodrugs: in vitro stability at pH 5	1992	Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7	Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID649895	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1278485	Antibacterial activity against Escherichia coli at 10 ug/ml by disc diffusion method	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID530345	Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID542742	Antimicrobial activity against Citrobacter freundii D26 expressing qnrB6 and CTX-M-9G genes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.
AID251698	Zone of inhibition of Klebsiella pneumoniae at compound concentration of 80 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID251671	Zone of inhibition of Bacillus subtilis at compound concentration of 40 mg/mL	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Synthesis and in vitro study of novel Mannich bases as antibacterial agents.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID574545	Antimicrobial activity against community-associated methicillin-resistant Staphylococcus aureus USA300	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID561107	Antibacterial activity against Pasteurella multocida BB1041 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID532184	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae SY26 harboring GyrA S83I, ParC S80I mutant, wild-type GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID599143	Lipophilicity, log P of the compound	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID139109	Effect on Candida albicans nephritis and Meningitis in Immunosuppressed Mice kidney	1996	Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4	High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID1889629	Antibacterial activity against Acinetobacter baumannii assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID94203	Antibacterial activity against Klebsiella pneumoniae at a concentration of 40 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1889622	Antibacterial activity against Staphylococcus aureus 25923 assessed as inhibition of bacterial growth by two fold serial dilution method	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.
AID577204	Antimicrobial activity against Escherichia coli O157:H7 PT-40 in stationary phase encoding Stx-2 gene by broth macrodilution assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID1890858	Antibacterial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID425395	Antibacterial activity against Escherichia coli isolates isolated from patients with Crohn's disease at 100 ug/disk by susceptibility testing disk method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID561106	Antibacterial activity against Pasteurella multocida BB1040 harboring plasmid pB1000 bearing blaROB-1 gene and plasmid pB9956 bearing tetH gene by CLSI M31-A3 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1404677	Synergistic antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in presence of TMP-Cl after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID64417	Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID532193	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii TJ15T harboring wild-type GyrA, ParC, GyrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID289694	Antibacterial activity against Pasteurella multocida at40 mg/ml by paper disc method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID535897	Antimicrobial activity against aac(6')-Ib-cr-positive Citrobacter freundii JS33 harboring GyrA T83I mutant, wild-type ParC, GyrB, qnrA and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID70307	Antibacterial activity against Escherichia coli at a concentration of 80 ug/mL	2003	Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21	QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1496671	Antibacterial activity against Pseudomonas aeruginosa NCIM 2036 after 24 hrs by broth micro dilution method
AID577197	Increase in Stx2 gene expression in Escherichia coli O157:H7 PT-32 at 0.5 X MIC by ELISA	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Different classes of antibiotics differentially influence shiga toxin production.
AID649898	Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days	2012	European journal of medicinal chemistry, Apr, Volume: 50	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID289693	Antibacterial activity against Pasteurella multocida at 30 mg/ml by paper disc method	2007	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3	Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID557795	Antimicrobial activity against Proteus mirabilis 06-489 isolated from infected human urinary tract by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.
AID425619	Cmax in immunodeficiency virus-infected patient at 800 mg, po by high-pressure liquid chromatography	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
AID1404666	Synergistic antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in presence of TMP-Cl after 20 hrs by broth microdilution-based checkerboard titration assay	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID532202	Antimicrobial activity against aac(6')-Ib-cr-positive Klebsiella pneumoniae WH99 harboring wild-type GyrA, ParC, GyrB and qnrB genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID574546	Antimicrobial activity against community-associated methicillin-resistant Staphylococcus aureus Sanger 252	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID535891	Antimicrobial activity against aac(6')-Ib-cr-negative Citrobacter freundii JN64 harboring GyrA T83I, wild-type ParC, GyrB and qnrA genes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID497903	Inhibition of IPTG-stimulated Escherichia coli K-12 folC at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID497730	Inhibition of IPTG-stimulated Escherichia coli K-12 yjeE at 8 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID497904	Inhibition of IPTG-stimulated Escherichia coli K-12 ribA at 4 fold MIC by microarray analysis	2009	Nature chemical biology, Nov, Volume: 5, Issue:11	Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3525 (64.85)	18.7374
1990's	302 (5.56)	18.2507
2000's	327 (6.02)	29.6817
2010's	746 (13.72)	24.3611
2020's	536 (9.86)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	680 (11.70%)	5.53%
Reviews	238 (4.09%)	6.00%
Case Studies	754 (12.97%)	4.05%
Observational	4 (0.07%)	0.25%
Other	4,137 (71.17%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (129)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma [NCT00002850]	Phase 3	212 participants (Actual)	Interventional	1997-03-31	Completed
Prospective Randomized Clinical Trial Comparing Efficacy Surgical Versus Medical Treatment of Osteomyelitis in Diabetic Foot Ulcers [NCT01137903]		88 participants (Anticipated)	Interventional	2010-04-30	Recruiting
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana [NCT01086878]	Phase 4	222 participants (Anticipated)	Interventional	2009-02-28	Completed
B-Lymphocyte Immunotherapy in Islet Transplantation: Single Subject Modification to Calcineurin-Inhibitor Based Immunosuppression for Initial Islet Graft (CIT-0501) [NCT01049633]		0 participants	Expanded Access		No longer available
Six- Versus Twelve-Week Therapy for Non-Surgically-Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study [NCT02123628]	Phase 4	40 participants (Actual)	Interventional	2007-06-30	Completed
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial [NCT05925309]		356 participants (Anticipated)	Interventional	2023-07-01	Recruiting
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (T [NCT04368559]	Phase 3	462 participants (Anticipated)	Interventional	2020-05-11	Recruiting
Treatment of Pneumocystis in COPD (the TOPIC Study) [NCT05418777]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2022-09-28	Terminated(stopped due to lack of enrollment)
Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections [NCT05577273]		1,000 participants (Anticipated)	Interventional	2018-08-14	Enrolling by invitation
Fluoroquinolone Associated Disability [NCT03535558]		239,306 participants (Actual)	Observational	2018-05-17	Completed
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants [NCT01349738]		200 participants (Anticipated)	Observational	2011-05-31	Enrolling by invitation
A Randomized Study of Cotrimoxazole Prophylaxis and Longer Breastfeeding Duration to Improve Survival Among HIV-Exposed Infants in Botswana [NCT01229761]	Phase 2	3,724 participants (Anticipated)	Interventional	2011-05-31	Completed
Does Post-operative Antibiotic Prophylaxis Reduce Urinary Tract Infection Rates After Holmium Laser Enucleation of Prostate? a Prospective Randomized Multi-center Study [NCT05274672]	Phase 4	100 participants (Anticipated)	Interventional	2022-03-01	Not yet recruiting
A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria [NCT00948896]	Phase 3	600 participants (Actual)	Interventional	2010-06-30	Completed
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
Effect of Antibiotics on Urinary Microbiome: Randomized Trial [NCT04230746]	Early Phase 1	0 participants (Actual)	Interventional	2023-10-31	Withdrawn(stopped due to funding , recruitment issues)
Randomized Clinical Trial to Assess Whether the Duration of Cotrimoxazole Preventive Therapy in HIV Patients With CD4 Counts >350 CD4 Cells/µL by Antiretroviral Treatment Influences the Rate of Carriage of Multidrug-resistant Bacteria [NCT03087890]	Phase 4	537 participants (Actual)	Interventional	2017-03-30	Completed
Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis [NCT00000816]	Phase 4	370 participants	Interventional		Completed
Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial) [NCT03235947]	Phase 4	82 participants (Actual)	Interventional	2016-09-07	Completed
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01595438]	Phase 3	598 participants (Actual)	Interventional	2012-10-31	Completed
Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial [NCT03042260]	Phase 4	310 participants (Anticipated)	Interventional	2017-03-01	Recruiting
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Treatment of Uncomplicated Skin and Soft Tissue Infections [NCT03637400]	Phase 2	462 participants (Anticipated)	Interventional	2018-11-26	Recruiting
Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder: a Randomized Controlled Trial [NCT05519072]	Phase 4	140 participants (Anticipated)	Interventional	2022-08-16	Recruiting
A Randomized Controlled Trial of Antibiotic Prophylaxis in Children With Pyelonephritis in the Abscence of Vesicoureteral Reflux [NCT00752375]	Phase 3	0 participants (Actual)	Interventional	2009-02-28	Withdrawn(stopped due to No participants)
A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV [NCT00080119]	Phase 2/Phase 3	1,354 participants (Actual)	Interventional	2004-02-29	Terminated(stopped due to Data Safety Monitoring Board (DSMB) recommended stopping study due to futility)
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00061945]	Phase 1/Phase 2	302 participants (Actual)	Interventional	2003-06-30	Completed
Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (C [NCT01101412]	Phase 1/Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study was not opened.)
A Randomized, Prospective, Single-Blinded Control Trial to Assess the Need for Antibiotic Prophylaxis With Routine Ureteral Stent Removal After Kidney Stone Procedure [NCT02944825]		80 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Sulfamethoxazole for the Treatment of Primary PREPL Deficiency (In Dutch: Sulfamethoxazole Ter Behandeling Van Primaire PREPL deficiëntie) [NCT02640443]	Phase 2	15 participants (Anticipated)	Interventional	2015-10-31	Enrolling by invitation
Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales (PACUTI) [NCT05224401]	Phase 3	330 participants (Anticipated)	Interventional	2023-05-29	Recruiting
Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus [NCT00730028]	Phase 2	1,310 participants (Actual)	Interventional	2009-04-30	Completed
Antibiotic Comparison Exacerbation COPD [NCT00791505]	Phase 3	170 participants (Actual)	Interventional	2002-07-31	Completed
Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole (TMP-SMX) Plus Rifampicin With a Regimen of Linezolid in the Treatment of Infections Caused by Methicillin-resistant Staphylococcus Aureus (MRSA) [NCT00711854]	Phase 4	150 participants (Actual)	Interventional	2009-01-31	Completed
Early Oral Step-down Antibiotic Therapy Versus Continuing Intravenous Therapy for Uncomplicated Gram-negative Bacteraemia (the INVEST Trial) [NCT05199324]	Phase 4	720 participants (Anticipated)	Interventional	2022-04-01	Recruiting
A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Pediatric Patients With Acute Bronchitis [NCT02879981]		51 participants (Actual)	Observational	2016-11-10	Completed
A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Adult Patients With Acute Bronchitis [NCT02902640]		52 participants (Actual)	Observational	2016-11-15	Completed
A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics [NCT00679302]	Phase 4	161 participants (Actual)	Interventional	2006-07-31	Completed
Randomized, Multi-Center Comparative Trial of Tacrolimus w/Steroids and Standard Daclizumab Induction vs a Novel Steroid-Free Tacrolimus Based Immunosuppression Protocol w/ Extended Daclizumab Induction in Pediatric Renal Transplantation [NCT00141037]	Phase 1/Phase 2	130 participants (Actual)	Interventional	2004-03-31	Completed
A Randomized, Open-label Phase III Study of Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Combination With Standard Therapy in Patients With Newly Diagnosed Multiple Myeloma [NCT02624440]	Phase 2	300 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Randomized, Double-Blinded Evaluation of Rifabutin Based Therapy for Eradication of Staphylococcus Aureus Carriage in HIV Infected Individuals With Prior Skin and Skin Structure Infections [NCT00869518]	Phase 2	12 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Poor enrollment)
Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949]	Phase 3	344 participants (Actual)	Interventional	2016-10-31	Completed
Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Placebo Added to Standard Treatment of Uncomplicated Cellulitis in Emergency Department Patients [NCT00676130]		153 participants (Actual)	Interventional	2007-05-31	Completed
"Strategies Using Off-Patent Antibiotics for Methicillin-Resistant Staphylococcus Aureus (STOP MRSA) - A Phase IIB, Multi-Center, Randomized, Double-Blind Clinical Trial" [NCT00729937]	Phase 2/Phase 3	2,265 participants (Actual)	Interventional	2009-04-30	Completed
A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS [NCT00000640]	Phase 3	290 participants	Interventional		Completed
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Pneumonia in AIDS [NCT00000715]	Phase 3	240 participants	Interventional		Completed
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS [NCT00001014]	Phase 3	302 participants	Interventional		Completed
Interactions Between HIV and Malaria in African Children [NCT00527800]	Phase 3	351 participants (Actual)	Interventional	2007-08-31	Completed
The Use of Adjuvant Antibiotic Therapy After Incision and Drainage for Pediatric Abscess: A Prospective, Randomized, Double-blinded, Placebo-Controlled Trial [NCT00900510]		0 participants (Actual)	Interventional	2009-05-31	Withdrawn(stopped due to Recruitment of this population in the hospital setting not practical.)
A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections [NCT01049438]		31 participants (Actual)	Interventional	2006-08-31	Completed
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas [NCT01967758]	Phase 1	11 participants (Actual)	Interventional	2014-01-08	Completed
A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections [NCT02044965]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2015-01-31	Recruiting
A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients [NCT00000748]	Phase 3	2,500 participants	Interventional		Completed
Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites [NCT00000826]	Phase 1	48 participants	Interventional		Completed
Randomized Controlled Study of a Computer Stop Order Versus Routine Practice When Trimethoprim/Sulfamethoxazole is Ordered Concurrently With Warfarin [NCT00870298]		1,971 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to four adverse events encountered)
An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum, Streptococcus Pneumoniae, and Escherichia Coli [NCT00137657]	Phase 4	1,478 participants	Interventional	2002-02-28	Completed
H-23187: Probiotic Prophylaxis Against Recurrent Pediatric Urinary Tract Infection [NCT00789464]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Withdrawn by PI)
Trimethoprim-sulfamethoxazole vs. Placebo After Hypospadias Repair: a Multicenter, Double-blind, Randomized Trial [NCT02096159]		93 participants (Actual)	Interventional	2014-03-31	Active, not recruiting
A Prospective, Randomized, Blind, Multicenter Trial Comparing Orally Administered Trimethoprim-sulfamethoxazole With Intravenously Administered Cefuroxime and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery [NCT00613769]	Phase 4	1,073 participants (Actual)	Interventional	2007-09-30	Completed
Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy [NCT04502095]	Phase 4	100 participants (Anticipated)	Interventional	2020-09-02	Recruiting
Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole [NCT02734732]	Phase 2	2,800 participants (Anticipated)	Interventional	2015-04-30	Recruiting
Population Pharmacokinetic Analysis of Sulfamethoxazole and Trimethoprim in Normal Weight, Overweight, and Obese Volunteers [NCT01167452]	Phase 4	36 participants (Actual)	Interventional	2010-07-31	Completed
Trimethoprim-sulfamethoxazole Versus Placebo in the Treatment of Cutaneous Abscesses in the Emergency Department [NCT00867789]		140 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to Slow enrollment due to subjects not meeting inclusion/exclusion criteria)
Evaluation of the Interaction Between Low Dose Trimethoprim/Sulfamethoxazole and Zidovudine [NCT00000732]		10 participants	Interventional		Completed
Trimethoprim-Sulfamethoxazole or Levofloxacin? A Retrospective Cohort Study of Targeted Therapy for Stenotrophomonas Maltophilia Blood Stream and Lower Respiratory Tract Infections [NCT04639817]		1,621 participants (Actual)	Observational	2020-08-14	Completed
International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS [NCT00302341]	Phase 3	48 participants (Actual)	Interventional	2006-05-31	Terminated(stopped due to FDA Clinical Hold as of 12/21/07 due to safety concerns)
Empiric Therapy With Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High MRSA Prevalence: A Prospective Randomized Trial [NCT00428818]		75 participants	Interventional	2005-08-31	Completed
Use of Antibiotic Prophylaxis on Urethral Catheter Withdrawal: A Randomized Double-Blind Placebo-Controlled Trial [NCT00126698]	Phase 4	100 participants	Interventional	2005-01-31	Completed
Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection: a Non-Inferiority Trial [NCT03508921]	Phase 4	22 participants (Actual)	Interventional	2018-07-01	Terminated(stopped due to Early termination due to recruitment and follow-up challenges during the pandemic)
A Prospective, Randomized Trial Comparing Vancomycin With Trimethoprim/Sulfamethoxazole for the Treatment of MRSA Osteomyelitis [NCT00324922]	Phase 3	2 participants (Actual)	Interventional	2006-05-01	Completed
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS [NCT00001013]	Phase 3	364 participants	Interventional		Completed
A Double-Blind Randomized Trial of Steroid Withdrawal in Sirolimus- and Cyclosporine-Treated Primary Transplant Recipients [NCT00023244]	Phase 2	274 participants (Actual)	Interventional	2001-01-31	Terminated(stopped due to Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferative disorder)
Prophylactic Antibiotics in Measles Infection. A Community-Based Randomised Double-Blind Placebo-Controlled Trial in Guinea-Bissau [NCT00168532]	Phase 3	218 participants	Interventional	1998-01-31	Completed
Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting [NCT05702762]	Phase 2	160 participants (Anticipated)	Interventional	2022-10-01	Recruiting
The Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections [NCT01507974]		220 participants (Actual)	Interventional	2012-01-16	Completed
Comparative Study of Efficacy of Two Antifolates Prophylactic Strategies Against Malaria in HIV Positive Pregnant Women (MACOMBA Study) [NCT01746199]	Phase 3	193 participants (Actual)	Interventional	2013-12-31	Completed
The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases [NCT01747278]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis [NCT01631617]	Phase 2	130 participants (Anticipated)	Interventional	2012-09-18	Recruiting
Prospective,Randomized,Open Label,European Multicenter Study of the Efficacy of the Linezolid-rifampin Combination Versus Standard of Care in the Treatment of Gram-positive. [NCT01757236]	Phase 2	100 participants (Anticipated)	Interventional	2012-10-31	Recruiting
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection [NCT01792804]	Phase 3	215 participants (Actual)	Interventional	2013-12-31	Completed
Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation. Randomized Controlled Trial. [NCT01820897]	Phase 4	130 participants (Anticipated)	Interventional	2013-04-30	Completed
Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP) [NCT01659866]	Phase 4	563 participants (Actual)	Interventional	2012-08-31	Completed
Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS Patients [NCT00002283]		0 participants	Interventional		Completed
Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II [NCT00002571]	Phase 2	52 participants (Actual)	Interventional	1994-06-30	Completed
Influence of Trimethoprim-sulfamethoxazole for the Recurrence of Retinochoroiditis Toxoplasma Gondii [NCT01449877]	Phase 3	141 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome [NCT00002002]		0 participants	Interventional		Completed
A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to [NCT00000730]	Phase 3	240 participants	Interventional		Terminated
Pilot Study in AIDS-Related Lymphomas [NCT00002524]	Phase 2	46 participants (Actual)	Interventional	1993-06-30	Completed
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions [NCT03014687]	Phase 4	116 participants (Anticipated)	Interventional	2017-07-01	Recruiting
A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intratumoral Injection [NCT00004216]	Phase 1	0 participants	Interventional	1999-08-31	Completed
A Randomised Controlled Trial of Continuing Immunoglobulin Therapy, or Stopping With or Without Prophylactic Antibiotics, on Infection Rate in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies. [NCT05678621]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2023-01-31	Not yet recruiting
Islet Transplantation for Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression (ITN005CT) [NCT00014911]	Phase 2	36 participants (Actual)	Interventional	2001-04-30	Completed
Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis [NCT01832987]	Phase 2	12 participants (Actual)	Interventional	2013-10-31	Completed
Trimethoprim-Sulfamethoxazole Effects on the Nasal Microbiome in Granulomatosis With Polyangiitis [NCT03919435]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2019-03-27	Active, not recruiting
Randomized Non-inferiority Trial of 3 Versus 10 Days of Trimethoprim-Sulfamethoxazole in Community-Associated Skin Abscesses After Surgical Drainage [NCT02024867]		249 participants (Actual)	Interventional	2010-02-28	Completed
The Effect of Rectal Swab Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy on Infectious Complications and Cost of Care: A Randomized Controlled Trial in the Netherlands. [NCT03228108]	Phase 4	1,538 participants (Actual)	Interventional	2018-04-03	Completed
Evaluation of the Interaction Between High Dose Trimethoprim/Sulfamethoxazole and Zidovudine [NCT00000734]		10 participants	Interventional		Completed
Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia [NCT00002120]	Phase 1	20 participants	Interventional		Completed
A Randomized, Phase II/III, Double-Blind, Two-Armed Study of Micronized Atovaquone and Azithromycin (AT/AZ) as Compared to Trimethoprim-Sulfamethoxazole (TMP/SMX) in the Prevention of Serious Bacterial Infections When Used in Children Aged 3 Months to 19 [NCT00000811]	Phase 2	690 participants	Interventional		Completed
A Randomized, Double-Blind Study of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients [NCT00000655]	Phase 2	300 participants	Interventional		Completed
A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection [NCT00000991]	Phase 3	600 participants	Interventional		Completed
A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT) [NCT00000727]	Phase 3	322 participants	Interventional		Completed
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3 [NCT01632891]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2014-01-10	Completed
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01599806]	Phase 3	641 participants (Actual)	Interventional	2012-10-31	Completed
Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. [NCT00382343]	Phase 4	96 participants (Actual)	Interventional	1999-11-30	Completed
Recurrent Urinary Tract Infections in Adult Women: a Pilot Study With Oral D Mannose [NCT01808755]	Phase 3	60 participants (Actual)	Interventional	2012-01-31	Completed
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe) [NCT01349192]	Phase 2	47 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects)
What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Oncologic Surgery to Reduce Early Wound Complications [NCT05823467]		105 participants (Anticipated)	Interventional	2023-06-26	Recruiting
Prophylactic Antibiotics Following Distal/Mid-shaft Hypospadias Repair: Are They Necessary? [NCT02593903]		67 participants (Actual)	Interventional	2014-03-04	Completed
Comparison of Post op Outcomes in Endoscopic Sinus Surgery Using Varying Nasal Sinus Irrigations. Saline vs. Saline and Budesonide vs Saline, Budesonide, and Culture Directed Topical Antibiotics [NCT03303677]	Phase 3	0 participants (Actual)	Interventional	2018-04-01	Withdrawn(stopped due to Withdrawn by sponsor)
"Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children" [NCT01595529]	Phase 2	717 participants (Actual)	Interventional	2012-05-18	Completed
Persistent MRSA Eradication Protocol (PMEP) [NCT01594827]	Phase 2	29 participants (Actual)	Interventional	2012-10-31	Completed
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia [NCT04851015]	Phase 3	300 participants (Anticipated)	Interventional	2022-06-30	Not yet recruiting
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) [NCT03489629]	Phase 2	42 participants (Anticipated)	Interventional	2018-04-03	Recruiting
Antibiotic Profile of Pathogenic Bacteria Isolated From Postsurgical Site Infections in Public Hospitals in Northern Jordan [NCT05106803]		24 participants (Actual)	Observational	2019-08-01	Completed
Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media [NCT00189098]		101 participants (Actual)	Interventional	2003-02-28	Completed
A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects [NCT01469637]	Phase 1	44 participants (Actual)	Interventional	2011-11-07	Completed
Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract [NCT02021006]	Phase 3	292 participants (Actual)	Interventional	2013-12-31	Active, not recruiting
Phase 3 Study Comparing Bactrim to Placebo in the Management of Abscesses < 5cm in the Pediatric Population. [NCT00691600]	Phase 3	23 participants (Actual)	Interventional	2007-12-31	Completed
A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess [NCT01723150]	Phase 4	152 participants (Actual)	Interventional	2013-11-05	Completed
Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) [NCT00405704]	Phase 3	607 participants (Actual)	Interventional	2007-05-31	Completed
Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK [NCT02475876]	Phase 1	51 participants (Actual)	Interventional	2015-11-30	Completed
Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial. [NCT03173053]		63 participants (Actual)	Interventional	2018-02-08	Terminated(stopped due to Results interim-analysis)
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis [NCT05398679]	Phase 4	360 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections [NCT03378427]		35 participants (Actual)	Interventional	2018-08-28	Completed
Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study [NCT05302531]	Phase 1	10 participants (Anticipated)	Interventional	2022-12-09	Recruiting
A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa [NCT02028676]	Phase 4	1,206 participants (Actual)	Interventional	2007-03-31	Completed
Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2) [NCT02282293]	Phase 3	200 participants (Actual)	Interventional	2014-12-09	Completed
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS) [NCT02168816]	Phase 2	30 participants (Actual)	Interventional	2014-03-19	Terminated(stopped due to The study was stopped for feasibility (i.e., low recruitment))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00002850 (1) [back to overview]	Proportion of Patients Experiencing a Serious Bacterial Infection
NCT00014911 (6) [back to overview]	Percent of Participants With Partial Islet Function One Year Post Final Islet Transplantation.
NCT00014911 (6) [back to overview]	Serum Creatinine Levels for Participants in the Extended Follow-up Study Phase
NCT00014911 (6) [back to overview]	Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.
NCT00014911 (6) [back to overview]	HbA1c Plasma Laboratory Values for Participants in the Extended Follow-up Study Phase
NCT00014911 (6) [back to overview]	Percent of Participants That Achieved Insulin Independence From First Transplant
NCT00014911 (6) [back to overview]	Percent of Participants With Detectable Fasting Basal C-Peptide Levels
NCT00061945 (6) [back to overview]	Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]	Number of Participants Achieving Complete Remission
NCT00061945 (6) [back to overview]	Disease-free Survival, for Only Complete Response Patients
NCT00061945 (6) [back to overview]	Overall Survival
NCT00061945 (6) [back to overview]	Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)
NCT00061945 (6) [back to overview]	Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
NCT00080119 (9) [back to overview]	Time From Randomization to Death Among HIV-infected and Perinatally Exposed, HIV-uninfected Children
NCT00080119 (9) [back to overview]	Time From Randomization to Development of TB Disease Among HIV Infected and Perinatally Exposed, HIV-uninfected Children
NCT00080119 (9) [back to overview]	Time From Randomization to Development of TB Infection Among HIV-infected and Perinatally Exposed, HIV-uninfected Children
NCT00080119 (9) [back to overview]	Time From Randomization to Development of TB Infection or Death Among HIV-infected Children
NCT00080119 (9) [back to overview]	Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children
NCT00080119 (9) [back to overview]	Time From Randomization to HIV Disease Progression or Death Among HIV-infected Children
NCT00080119 (9) [back to overview]	Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children
NCT00080119 (9) [back to overview]	Time From Randomization to First New Grade 3 or Worse Adverse Event Among HIV-infected and Perinatally Exposed, HIV-uninfected Children
NCT00080119 (9) [back to overview]	Time From Randomization to Development of TB Disease or Death Among Perinatally Exposed, HIV-uninfected Children
NCT00141037 (2) [back to overview]	The Difference in Linear Growth by Treatment Assignment at 1 Year Post Kidney Transplantation
NCT00141037 (2) [back to overview]	Comparison by Treatment Assignment in the Number of Biopsy-Proven Acute Rejections Within 12 Months Post Kidney Transplantation
NCT00189098 (6) [back to overview]	Number of Participants With Otomicroscopic Signs of Otorrhea in Either Ear
NCT00189098 (6) [back to overview]	Number of Patients Who Used Systemic Antibiotics Other Than the Study Medication Between 6 and 12 Weeks Follow-up.
NCT00189098 (6) [back to overview]	Number of Patients Who Used Systemic Antibiotics Other Than the Study Medication Between 12 Weeks and 1 Year Follow-up.
NCT00189098 (6) [back to overview]	Number of Patients Who Used Additional Antibiotic Eardrops Between 6 to 12 Week Follow-up
NCT00189098 (6) [back to overview]	Number of Patients Who Underwent Ear Nose and Throat Surgery Between 12 Weeks and 1 Year Follow-up.
NCT00189098 (6) [back to overview]	Number of Patients Who Used Additional Antibiotic Eardrops Between 12 Weeks to 1 Year Follow-up
NCT00405704 (8) [back to overview]	Presence of E.Coli Resistant to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Based on Rectal Swab)
NCT00405704 (8) [back to overview]	Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up
NCT00405704 (8) [back to overview]	Recurrent Febrile or Symptomatic UTI With Any Resistant Pathogen
NCT00405704 (8) [back to overview]	Recurrent Febrile or Symptomatic UTI With Resistant E. Coli
NCT00405704 (8) [back to overview]	Outcome Renal Scarring
NCT00405704 (8) [back to overview]	Severe Renal Scarring on Outcome Scan
NCT00405704 (8) [back to overview]	Treatment Failure Composite
NCT00405704 (8) [back to overview]	New Renal Scarring on Outcome Scan
NCT00676130 (2) [back to overview]	Progression to Abscess
NCT00676130 (2) [back to overview]	Relative Efficacy
NCT00679302 (2) [back to overview]	New Lesion Development and Spread of Skin Abscesses (on Subject)
NCT00679302 (2) [back to overview]	Skin Abscess Resolution
NCT00691600 (3) [back to overview]	Number of Participants Requiring New or Modified Antibiotics for Failure of Abscess to Resolve
NCT00691600 (3) [back to overview]	Number of Participants Requiring Admission for Failure of Abscess Resolution
NCT00691600 (3) [back to overview]	Number of Participants With Abscess Resolution
NCT00729937 (31) [back to overview]	Number of Participants With Infections in Household Contacts Through the EFV Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Infections in Household Contacts Through the TOC Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants With Infections in Household Contacts Through the TOC Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants by Composite Clinical Outcome at the TOC Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants Reporting 1-14 Days of Analgesic Use in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants Reporting 1-14 Days of Analgesic Use in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Adverse Events Considered Associated With the Study Product by MedDRA System Organ Class
NCT00729937 (31) [back to overview]	Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Clinical Cure as of the TOC Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants With Reduction in Erythema Dimensions by 5% Intervals at the End-of-therapy Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants With Reduction in Erythema Dimensions by 5% Intervals at the End-of-therapy Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Reduction in Erythema Dimensions by 5% Intervals at the On-therapy Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants With Reduction in Erythema Dimensions by 5% Intervals at the On-therapy Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Reduction in Erythema Dimensions by 5% Intervals at the TOC Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants With Reduction in Erythema Dimensions by 5% Intervals at the TOC Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Each Microbiological Outcome at the TOC Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Mean Days Missed From Normal Activities in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Mean Days Missed From Normal Activities in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants Requiring Surgical Intervention Through the Extended Follow-up Visit (EFV) in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants Requiring Surgical Intervention Through the Extended Follow-up Visit (EFV) in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants Requiring Surgical Intervention Through the TOC Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants Requiring Surgical Intervention Through the TOC Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants Who Developed a Recurrent Infection at the Original Infection Site Through the EFV Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants Who Developed a Recurrent Infection at the Original Infection Site Through the EFV Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants Who Developed a Recurrent Infection at the Original Infection Site Through the TOC Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants Who Developed a Recurrent Infection at the Original Infection Site Through the TOC Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Development of an Invasive Infection Through the EFV Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants With Development of an Invasive Infection Through the EFV Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Development of an Invasive Infection Through the TOC Visit in the Intent to Treat Population
NCT00729937 (31) [back to overview]	Number of Participants With Development of an Invasive Infection Through the TOC Visit in the Per Protocol Population
NCT00729937 (31) [back to overview]	Number of Participants With Infections in Household Contacts Through the EFV Visit in the Intent to Treat Population
NCT00730028 (8) [back to overview]	Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Evaluable Population.
NCT00730028 (8) [back to overview]	Percentage of Participants Achieving Clinical Cure at the One Month Follow-up (OMFU) Visit for the Intent-to-Treat (ITT) Population.
NCT00730028 (8) [back to overview]	Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population.
NCT00730028 (8) [back to overview]	Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Intent-to-Treat (ITT) Population.
NCT00730028 (8) [back to overview]	Number of Participants Reporting Adverse Events That Are Treatment Limiting.
NCT00730028 (8) [back to overview]	Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Intent-to-Treat (ITT) Population.
NCT00730028 (8) [back to overview]	Number of Participants Reporting Adverse Events.
NCT00730028 (8) [back to overview]	Percentage of Participants Achieving Clinical Cure at the End of Treatment (EOT) Visit for the Evaluable Population.
NCT00867789 (1) [back to overview]	Health Outcomes After Use With Trimethoprim-sulfamethaxazole
NCT00869518 (3) [back to overview]	Eradication of S. Aureus Colonization
NCT00869518 (3) [back to overview]	Eradication of S. Aureus Colonization
NCT00869518 (3) [back to overview]	Recurrent Skin and Skin Structure Infections (SSTI)
NCT00948896 (4) [back to overview]	Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs
NCT00948896 (4) [back to overview]	Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants
NCT00948896 (4) [back to overview]	Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants
NCT00948896 (4) [back to overview]	Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk
NCT01167452 (1) [back to overview]	Elimination Rate Constants for Sulfamethoxazole and Trimethoprim
NCT01349192 (4) [back to overview]	Antibiotic Use (Days of Use Per Subject)
NCT01349192 (4) [back to overview]	Pulmonary Exacerbations
NCT01349192 (4) [back to overview]	MRSA Culture Status
NCT01349192 (4) [back to overview]	Antibiotic Use (Proportion of Subjects)
NCT01469637 (2) [back to overview]	Area Under the Plasma Concentration Versus Time Curve Within a Dosing Interval at Steady-State (AUCss) for Sulfamethoxazole
NCT01469637 (2) [back to overview]	Maximum Plasma Concentration at Steady-State (Cmaxss) for Sulfamethoxazole
NCT01594827 (9) [back to overview]	Total Number of Pulmonary Exacerbations
NCT01594827 (9) [back to overview]	Change in Patient Reported Quality of Life (CFQ-R)(Respiratory)
NCT01594827 (9) [back to overview]	Change if FEV1% Predicted From Screening
NCT01594827 (9) [back to overview]	Time to First CF Exacerbation
NCT01594827 (9) [back to overview]	Time to First Anti-MRSA Antibiotics (After Treatment Period)
NCT01594827 (9) [back to overview]	Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture
NCT01594827 (9) [back to overview]	Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture
NCT01594827 (9) [back to overview]	Development of Antibiotic Resistance
NCT01594827 (9) [back to overview]	Change in Forced Expiratory Volume (FEV1)% Predicted From Baseline to Day 58
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01595438 (63) [back to overview]	Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant Escherichia Coli (E. Coli) and Klebsiella Pneumoniae (K. Pneumoniae) in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics.
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]	Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]	Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]	Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]	Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant E. Coli and K. Pneumoniae in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics.
NCT01595529 (12) [back to overview]	Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01599806 (63) [back to overview]	Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)
NCT01632891 (7) [back to overview]	Number of Participants With Uncomplicated Clinical Malaria
NCT01632891 (7) [back to overview]	Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance
NCT01632891 (7) [back to overview]	Number of Participants With Detectable Pf Gametocyte Density
NCT01632891 (7) [back to overview]	Log10(Pf Parasite Density)
NCT01632891 (7) [back to overview]	Time to First Pf SCP Clearance
NCT01632891 (7) [back to overview]	Change in log10(Pf Parasite Density) From Entry to Day 30
NCT01632891 (7) [back to overview]	Change in log10(Pf Gametocyte Density) From Entry to Day 30
NCT01659866 (1) [back to overview]	Number of Participants With Post-biopsy Infection.
NCT01808755 (1) [back to overview]	Days
NCT02024867 (6) [back to overview]	Treatment Failures Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus
NCT02024867 (6) [back to overview]	Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus
NCT02024867 (6) [back to overview]	Treatment Failures
NCT02024867 (6) [back to overview]	Recurrent Skin Infections Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus
NCT02024867 (6) [back to overview]	Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus
NCT02024867 (6) [back to overview]	Recurrent Skin Infections
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: All-cause Mortality
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 48
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 96
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 48
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 96
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Height-for-age Z-score
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV, Judged Definitely/Probably or Uncertain Whether Related to Lamivudine or Abacavir
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Suppressed HIV RNA Viral Load 48 Weeks After Randomisation
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Suppression of HIV RNA Viral Load 96 Weeks After Randomisation
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	CDM vs LCM, Induction ART: Suppression of HIV RNA Viral Load 144 Weeks After Baseline
NCT02028676 (58) [back to overview]	CDM vs LCM, Induction ART: Suppression of HIV RNA Viral Load 72 Weeks After Baseline
NCT02028676 (58) [back to overview]	Cotrimoxazole: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	Cotrimoxazole: All-cause Mortality
NCT02028676 (58) [back to overview]	Cotrimoxazole: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	Cotrimoxazole: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	Cotrimoxazole: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	Cotrimoxazole: Height-for-age Z-score
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Clinical and Diagnostic Positive Malaria
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Hospitalisation or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Severe Pneumonia
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 3 Severe Recurrent Pneumonia or Diarrhoea
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	Induction ART: Change From Baseline in CD4% 72 Weeks After ART Initiation
NCT02028676 (58) [back to overview]	Induction ART: Change From Baseline in CD4% to 144 Weeks From ART Initiation
NCT02028676 (58) [back to overview]	Induction ART: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Induction ART: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: All-cause Mortality
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Cessation of First-line Regimen for Clinical/Immunological Failure
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 144
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Height-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New ART-modifying Adverse Event
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New Grade 3 or 4 Adverse Event Definitely/Probably or Uncertainly Related to ART
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New or Recurrent WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM: Change From Baseline in CD4% to Week 144
NCT02028676 (58) [back to overview]	LCM vs CDM: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks) at 48 Weeks
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks) at 96 Weeks
NCT02282293 (7) [back to overview]	Composite Adverse Birth Outcome (Proportion With Low Birth Weight (<2500 gm), Spontaneous Abortion (<28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (<37 Weeks)
NCT02282293 (7) [back to overview]	Incidence of Malaria, Pregnant Women
NCT02282293 (7) [back to overview]	Number of Monthly Routine Visits With Positive Blood Samples for Parasites
NCT02282293 (7) [back to overview]	Number of Participants With Placental Malaria
NCT02282293 (7) [back to overview]	Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia
NCT02282293 (7) [back to overview]	Maternal Parasitemia at Delivery by Microscopy and LAMP
NCT02282293 (7) [back to overview]	Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)
NCT03508921 (3) [back to overview]	Urinary Retention
NCT03508921 (3) [back to overview]	Recurrent Urinary Tract Infection
NCT03508921 (3) [back to overview]	Post Procedural- Urinary Tract Infection
NCT05418777 (14) [back to overview]	Interval Between Exacerbations of COPD
NCT05418777 (14) [back to overview]	Change in the COPD Assessment Test
NCT05418777 (14) [back to overview]	Time to Return to Baseline Oxygen for the Current AECOPD
NCT05418777 (14) [back to overview]	Number of Urgent Care Visits (Total)
NCT05418777 (14) [back to overview]	Number of Urgent Care Visits (Related to COPD)
NCT05418777 (14) [back to overview]	Number of Hospital Admissions (Total)
NCT05418777 (14) [back to overview]	Number of Hospital Admissions (Related to COPD)
NCT05418777 (14) [back to overview]	Need for Mechanical Ventilation
NCT05418777 (14) [back to overview]	Mortality
NCT05418777 (14) [back to overview]	Length of Stay for Current AECOPD
NCT05418777 (14) [back to overview]	Interval Between Hospital Admissions
NCT05418777 (14) [back to overview]	Durability of Clearance of PJ From Treated Patients
NCT05418777 (14) [back to overview]	Clearance of PJ From Treated Patients
NCT05418777 (14) [back to overview]	Need for Medications to Treat COPD

Proportion of Patients Experiencing a Serious Bacterial Infection

This study evaluated the impact of prophylactic antibiotics on the incidence of serious bacterial infections (SBIs) during the first 2 months of treatment in patients with newly diagnosed multiple myeloma. Patients with multiple myeloma receiving initial chemotherapy were randomized on a 1:1:1 basis to daily ciprofloxacin, trimethoprim-sulfamethoxazole, or observation and evaluated for SBI for the first 2 months of treatment. (NCT00002850)
Timeframe: First three months of chemotherapy

Intervention	percentage of participants (Number)
Ciprofloxacin or Ofloxacin	12.5
TMP-SMX	6.8
No Prophylaxis	15.9

Intervention	Percent of Participants (Number)
	Insulin Independence at One Year	Insulin Independence with One Transplant	Insulin Independence with Two Transplants	Insulin Independence with Three Transplants
Islet Transplantation	44	14	17	14

Intervention	participants (Number)
Phase I - Alemtuzumab and Combination Chemotherapy	92
Phase II - Alemtuzumab and Combination Chemotherapy	145

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	58.6
Phase II - Alemtuzumab and Combination Chemotherapy	19.8

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	33.6
Phase II - Alemtuzumab and Combination Chemotherapy	23.1

Intervention	Percent of participants (Number)
	New >=grade 3 sign/symptom	New >= grade 3 peripheral neuropathy	New >=grade 3 lab abnormality	New >=grade 3 hemoglobin	New >=grade 3 ANC	New >=grade 3 platelets	New >=grade 3 SGOT	New >=grade 3 SGPT
HIVneg/INH	5.0	1.1	4.9	0.0	1.7	0.3	1.0	2.8
HIVneg/PL	4.2	0.3	4.6	0.0	0.3	0.0	2.8	4.4
HIVpos/INH	16.8	2.4	11.3	1.8	1.6	1.7	0.4	5.9
HIVpos/PL	11.7	0.8	10.1	1.2	3.5	0.9	2.5	4.0

Intervention	Standard Deviation Score (SDS) (Mean)
Steroid-Free Immunosuppression	0.37
Steroid-Based Immunosuppression	0.35

Intervention	participants (Number)
	At 6 weeks	At 12 weeks	At 12 months
Placebo	27	23	9
Sulfamethoxazole-trimethoprim	13	15	11

Intervention	participants (Number)
Abscess, Placebo	33
Abscess, TMP/SMX	20
Infected Wound, TMP/SMX	6
Infected Wound, Clindamycin	9
Cellulitis, Cephalexin and TMP/SMX	10
Cellulitis, Cephalexin	5

Intervention	participants (Number)
	Composite Clinical Cure	Composite Clinical Failure
Abscess, Placebo	396	137
Abscess, TMP/SMX	453	71
Cellulitis, Cephalexin	149	44
Cellulitis, Cephalexin and TMP/SMX	160	58
Infected Wound, Clindamycin	114	89
Infected Wound, TMP/SMX	113	85

Intervention	participants (Number)
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13	Day 14
Abscess, Placebo	58	38	45	47	27	34	27	34	24	14	19	19	15	146
Abscess, TMP/SMX	81	34	64	34	42	29	32	40	26	15	10	14	5	127
Cellulitis, Cephalexin	28	6	10	13	4	22	8	6	6	4	2	6	3	45
Cellulitis, Cephalexin and TMP/SMX	18	7	15	16	10	10	9	10	9	5	3	1	2	51
Infected Wound, Clindamycin	37	10	24	10	9	13	12	11	9	4	4	3	7	50
Infected Wound, TMP/SMX	32	15	18	16	9	13	13	8	4	6	2	4	2	59

Intervention	participants (Number)
	Cardiac disorders	Eye disorders	Gastrointestinal disorders	General disorders and administration site conditio	Infections and infestations	Injury, poisoning and procedural complications	Investigations	Metabolism and nutrition disorders	Musculoskeletal and connective tissue disorders	Nervous system disorders	Psychiatric disorders	Renal and urinary disorders	Reproductive system and breast disorders	Respiratory, thoracic and mediastinal disorders	Skin and subcutaneous tissue disorders	Vascular disorders
Abscess, Placebo	0	3	164	6	5	1	1	7	3	38	0	2	1	3	10	2
Abscess, TMP/SMX	0	1	198	11	4	0	0	11	3	44	1	0	0	0	14	0
Cellulitis, Cephalexin	0	0	73	2	1	0	0	0	0	20	0	0	0	0	7	0
Cellulitis, Cephalexin and TMP/SMX	0	0	87	2	1	0	0	3	0	16	0	1	1	0	15	0
Infected Wound, Clindamycin	1	0	93	1	1	0	0	4	0	15	0	0	1	0	6	0
Infected Wound, TMP/SMX	0	0	82	3	1	0	1	2	0	16	0	1	0	0	5	0

Intervention	participants (Number)
	Clinical Cure	Clinical Failure
Abscess, Placebo	457	76
Abscess, TMP/SMX	487	37
Cellulitis, Cephalexin	165	28
Cellulitis, Cephalexin and TMP/SMX	182	36
Infected Wound, Clindamycin	187	16
Infected Wound, TMP/SMX	182	16

Intervention	participants (Number)
	No reduction	>0%-5% reduction	>5%-10% reduction	>10%-15% reduction	>15%-20% reduction	>20%-25% reduction	>25%-30% reduction	>30%-35% reduction	>35%-40% reduction	>40%-45% reduction	>45%-50% reduction	>50%-55% reduction	>55%-60% reduction	>60%-65% reduction	>65%-70% reduction	>70%-75% reduction	>75%-80% reduction	>80%-85% reduction	>85%-90% reduction	>90%-95% reduction	>95%-100% reduction
Abscess, Placebo	5	0	1	0	0	0	2	0	2	0	2	4	0	2	4	3	6	4	7	9	531
Abscess, TMP/SMX	3	0	0	1	0	0	1	1	1	3	0	1	5	0	3	2	2	5	9	7	532
Cellulitis, Cephalexin	5	0	0	1	0	0	1	1	0	1	0	2	2	2	3	2	2	2	6	7	188
Cellulitis, Cephalexin and TMP/SMX	5	0	1	0	0	1	0	1	1	0	0	0	1	5	2	5	3	0	4	2	198
Infected Wound, Clindamycin	3	0	0	1	0	0	0	0	0	0	1	1	1	2	1	2	1	4	4	2	208
Infected Wound, TMP/SMX	3	0	0	1	0	1	1	0	0	3	1	2	1	3	2	3	2	1	2	5	197

Intervention	participants (Number)
	Presumed eradication	Persistence	New infection	Super-infection	Unclassified	Indeterminate
Abscess, Placebo	457	39	1	8	28	0
Abscess, TMP/SMX	487	15	0	4	18	0
Cellulitis, Cephalexin	165	0	0	0	11	17
Cellulitis, Cephalexin and TMP/SMX	182	0	0	0	13	23
Infected Wound, Clindamycin	187	6	1	0	9	0
Infected Wound, TMP/SMX	182	5	2	0	9	0

Intervention	percentage of participants (Number)
Cellulitis or Larger Abscess - Clindamycin	83.9
Cellulitis or Larger Abscess - TMP-SMX	78.2
Limited Abscess - Clindamycin	89.3
Limited Abscess - TMP-SMX	85.0
Limited Abscess - Placebo	73.9

Intervention	percentage of participants (Number)
Cellulitis or Larger Abscess - Clindamycin	73.1
Cellulitis or Larger Abscess - TMP-SMX	67.7
Limited Abscess - Clindamycin	78.6
Limited Abscess - TMP-SMX	73.0
Limited Abscess - Placebo	62.6

Intervention	percentage of participants (Number)
Cellulitis or Larger Abscess - Clindamycin	89.5
Cellulitis or Larger Abscess - TMP-SMX	88.2
Limited Abscess - Clindamycin	92.9
Limited Abscess - TMP-SMX	92.7
Limited Abscess - Placebo	80.5

Intervention	percentage of participants (Number)
Cellulitis or Larger Abscess - Clindamycin	80.3
Cellulitis or Larger Abscess - TMP-SMX	77.7
Limited Abscess - Clindamycin	83.1
Limited Abscess - TMP-SMX	81.7
Limited Abscess - Placebo	68.9

Intervention	percentage of participants (Number)
Cellulitis or Larger Abscess - Clindamycin	81.1
Cellulitis or Larger Abscess - TMP-SMX	75.4
Limited Abscess - Clindamycin	78.9
Limited Abscess - TMP-SMX	79.8
Limited Abscess - Placebo	72.4

Intervention	percentage of participants (Number)
Cellulitis or Larger Abscess - Clindamycin	89.2
Cellulitis or Larger Abscess - TMP-SMX	88.3
Limited Abscess - Clindamycin	90.9
Limited Abscess - TMP-SMX	94.2
Limited Abscess - Placebo	84.9

sulfamethoxazole

Description

Cross-References

Synonyms (278)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (10)

Drug Classes (4)

Protein Targets (25)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (52)

Molecular Functions (35)

Ceullar Components (22)

Bioassays (471)

Research

Studies (5,436)

Market Indicators

Research Demand Index: 116.75

Study Types

Clinical Trials (129)

Trial Overview

Trial Outcomes

Proportion of Patients Experiencing a Serious Bacterial Infection

Percent of Participants With Partial Islet Function One Year Post Final Islet Transplantation.

Serum Creatinine Levels for Participants in the Extended Follow-up Study Phase

Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation.

HbA1c Plasma Laboratory Values for Participants in the Extended Follow-up Study Phase

Percent of Participants That Achieved Insulin Independence From First Transplant

Percent of Participants With Detectable Fasting Basal C-Peptide Levels

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Number of Participants Achieving Complete Remission

Disease-free Survival, for Only Complete Response Patients

Overall Survival

Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

Time From Randomization to Death Among HIV-infected and Perinatally Exposed, HIV-uninfected Children

Time From Randomization to Development of TB Disease Among HIV Infected and Perinatally Exposed, HIV-uninfected Children

Time From Randomization to Development of TB Infection Among HIV-infected and Perinatally Exposed, HIV-uninfected Children

Time From Randomization to Development of TB Infection or Death Among HIV-infected Children

Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children

Time From Randomization to HIV Disease Progression or Death Among HIV-infected Children

Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children

Time From Randomization to First New Grade 3 or Worse Adverse Event Among HIV-infected and Perinatally Exposed, HIV-uninfected Children

Time From Randomization to Development of TB Disease or Death Among Perinatally Exposed, HIV-uninfected Children

The Difference in Linear Growth by Treatment Assignment at 1 Year Post Kidney Transplantation

Comparison by Treatment Assignment in the Number of Biopsy-Proven Acute Rejections Within 12 Months Post Kidney Transplantation

Number of Participants With Otomicroscopic Signs of Otorrhea in Either Ear

Number of Patients Who Used Systemic Antibiotics Other Than the Study Medication Between 6 and 12 Weeks Follow-up.

Number of Patients Who Used Systemic Antibiotics Other Than the Study Medication Between 12 Weeks and 1 Year Follow-up.

Number of Patients Who Used Additional Antibiotic Eardrops Between 6 to 12 Week Follow-up

Number of Patients Who Underwent Ear Nose and Throat Surgery Between 12 Weeks and 1 Year Follow-up.

Number of Patients Who Used Additional Antibiotic Eardrops Between 12 Weeks to 1 Year Follow-up

Presence of E.Coli Resistant to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Based on Rectal Swab)

Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up

Recurrent Febrile or Symptomatic UTI With Any Resistant Pathogen

Recurrent Febrile or Symptomatic UTI With Resistant E. Coli

Outcome Renal Scarring

Severe Renal Scarring on Outcome Scan

Treatment Failure Composite

New Renal Scarring on Outcome Scan

Progression to Abscess

Relative Efficacy

New Lesion Development and Spread of Skin Abscesses (on Subject)

Skin Abscess Resolution

Number of Participants Requiring New or Modified Antibiotics for Failure of Abscess to Resolve

Number of Participants Requiring Admission for Failure of Abscess Resolution

Number of Participants With Abscess Resolution

Number of Participants With Infections in Household Contacts Through the EFV Visit in the Per Protocol Population

Number of Participants With Infections in Household Contacts Through the TOC Visit in the Intent to Treat Population

Number of Participants With Infections in Household Contacts Through the TOC Visit in the Per Protocol Population

Number of Participants by Composite Clinical Outcome at the TOC Visit in the Per Protocol Population

Intervention	incidence per person-year at risk (Number)
	All grade 3-4 adverse events	Grade 3-4 AEs possibly related to study drugs	All serious adverse events	Elevated Temperature	Anemia	Thrombocytopenia	Elevated aspartate aminotransferase	Elevated alanine aminotransferase	Neutropenia	Malnutrition
HIV-exposed & Daily TS	0.659	0.062	0.330	0.206	0.206	0	0.041	0	0	0.021
HIV-exposed & Monthly DP	0.678	0.097	0.194	0.174	0.291	0.058	0.039	0	0	0.039
HIV-exposed & Monthly SP	1.478	0	0.453	0.532	0.631	0.118	0.020	0	0	0.020
HIV-exposed & no Chemoprevention	1.214	NA	0.411	0.431	0.705	0	0.039	0	0	0.020
HIV-unexposed & Daily TS	0.914	0.054	0.196	0.393	0.318	0.061	0.041	0.027	0.014	0
HIV-unexposed & Monthly DP	0.611	0.021	0.091	0.323	0.168	0.035	0.021	0.021	0.007	0
HIV-unexposed & Monthly SP	1.415	0.056	0.364	0.546	0.602	0.119	0.056	0.028	0.042	0
HIV-unexposed & no Chemoprevention	1.159	NA	0.178	0.542	0.384	0.123	0.048	0.027	0.021	0

Intervention	Episodes per person year at risk (Number)
	Randomization - 24 mo. of Age	Randomization -16 mo. of Age	17-24 mo. of Age
HIV-exposed & Daily TS	2.86	1.70	3.79
HIV-exposed & Monthly DP	1.83	0.90	2.67
HIV-exposed & Monthly SP	4.50	3.72	5.22
HIV-exposed & no Chemoprevention	6.28	5.42	7.04

Intervention	Episode per person year at risk (Number)
	6-24 mo. of Age	6-11 mo. of Age	12-24 mo. of Age
HIV-unexposed & Daily TS	5.21	3.27	6.32
HIV-unexposed & Monthly DP	3.02	1.49	3.88
HIV-unexposed & Monthly SP	6.73	5.51	7.41
HIV-unexposed & no Chemoprevention	6.95	6.41	7.24

Intervention	Incidence per person year at risk (Number)
	All incident episodes of malaria	Complicated malaria	All-cause hospital admissions
HIV-exposed & Daily TS	8.13	0.116	0.186
HIV-exposed & Monthly DP	6.78	0.044	0.089
HIV-exposed & Monthly SP	6.75	0.147	0.318
HIV-exposed & no Chemoprevention	9.08	0.161	0.459
HIV-unexposed & Daily TS	10.90	0.046	0.091
HIV-unexposed & Monthly DP	10.77	0	0.023
HIV-unexposed & Monthly SP	11.98	0.132	0.452
HIV-unexposed & no Chemoprevention	10.85	0.046	0.046

Intervention	h*ug/ml (Mean)
Sulfamethoxazole + MMX Placebo	786
Sulfamethoxazole + MMX Mesalazine/Mesalamine	909

Intervention	ug/ml (Mean)
Sulfamethoxazole + MMX Placebo	89.1
Sulfamethoxazole + MMX Mesalazine/Mesalamine	100

Intervention	Exacerbations (Number)
	Day 58	Day 118
Inhaled Placebo (Sterile Water) and Oral Antibiotics	1	3
Inhaled Vancomycin and Oral Antibiotics	0	0

Intervention	units on a scale (Mean)
	Day 29	Day 58
Inhaled Placebo (Sterile Water) and Oral Antibiotics	11.5	3.2
Inhaled Vancomycin and Oral Antibiotics	3.3	-4.4

Intervention	Days (Mean)
Inhaled Vancomycin and Oral Antibiotics	NA
Inhaled Placebo (Sterile Water) and Oral Antibiotics	68.4

Intervention	% predicted FEV1 (Median)
Inhaled Vancomycin and Oral Antibiotics	-2.5
Inhaled Placebo (Sterile Water) and Oral Antibiotics	1.0